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Automation compatibility is a prerequisite for in vitro transport and metabolism 
assays that are designed for screening large numbers of compounds at the early 
stages of drug discovery, in parallel with activity optimization. However, automation 
of more complex assays has also many benefits, even if it does not always increase 
the throughput of the assay directly. 
In this thesis work, a new automatable high throughput screening assay was 
developed for detecting different compound interactions with UGT1A6, one of the 
human intestinal UGT enzymes. The fluorescence-based assay relies on a robust 
probe reaction, glucuronidation of 1-naphthol by recombinant human UGT1A6, 
which yields a highly fluorescent product, 1-naphthylglucuronide. Under the 
optimized  assay  conditions,  the  plate  reader-based  analysis  method  was  able  to  
detect a given compound interaction with the enzyme, through the probe reaction, in 
a comparable manner to the (cumbersome) reference HPLC-based method. The new 
method can analyze the interaction of many different compounds with the UGT1A6 
simultaneously.  
The developed assay was then used to collect data for computational model 
development. The effects of different compounds on the probe glucuronidation rate 
were used for a classification model, based on an SVM method, and for 3D-QSAR 
models, based on CoMFA and CoMSIA analysis. Both the models indicated 
physicochemical parameters and functional groups that are important for the 
interaction of different compounds with the UGT1A6.  
Interactions of two drugs, diclofenac and indomethacin, were studied more 
thoroughly with the several UGT enzymes, including UGT1A6. The effect of pH on 
the interaction was examined in both human liver and intestinal microsomes, as well 
as with many individual recombinant human UGTs. The results indicated that the 
effects of pH were both enzyme and substrate dependent, suggesting that changes in 
the  enzyme,  probably  protonation  of  one  or  more  amino  acid  side  chain,  played  a  
major role in the observed effects.  
Finally, automation of three different types of cell-based assays, Caspase-Glo® 
3/7, sulforhodamine B and bidirectional Caco-2 monolayer transport assays, are 
described in detail. Although, the bidirectional Caco-2 assay was the most 
challenging for automation, due to the complex assay protocol and the sensitivity of 
the monolayer to mechanical stress, mainly caused by pipetting, automation 
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Robotic workstations were first established in clinical diagnostics to prepare samples 
for analysis in the early 1980s. Soon after, pharmaceutical industry started to apply 
them in drug activity and potency testing. In mid 1980s, the successful 
miniaturization of in vitro activity assays led to the establishment of high throughput 
screening concept, which, furthermore, increased the need for automation in the drug 
discovery laboratories. Indeed, automation is considered one of the main 
contributors to the fast increase in assay throughputs during the mid 1990s. More 
user-friendly workstations together with advancements in liquid handling and 
analytical techniques pushed the development towards even higher density assay 
formats.  
During the mid 1990s, the HTS concept emerged also to the ADMET 
(absorption, distribution, metabolism, excretion, toxicity) studies. At that time, it was 
noticed that a high number of compounds failed in clinical studies due to the poor 
pharmacokinetic properties and toxicity. That evoked need for more efficient testing 
of the pharmacokinetic properties before performing the laborious, expensive and 
non-ethical in vivo assays. The first HTS assays in the ADMET area were 
microsomal CYP, protein binding, Caco-2 permeability and cytotoxicity assays. 
Since the mid 1990s, the number of the assays has expanded. Especially, the 
growing understanding on the importance of the multiple drug transporters and 
metabolizing enzymes on pharmacokinetics of drugs in many organs, has paved the 
way towards new and more detailed mechanistic assays.  
One of the important organs, in which the drug transporters and metabolic 
enzymes affect the pharmacokinetics of drugs, is human intestine. Although the liver 
is considered the main metabolizing organ in the human body, contribution of 
intestinal metabolism in total metabolic clearance of many drugs is well recognized.   
Metabolic enzymes in the intestine have also been reported to take part in clinically 
relevant drug-drug interactions. The risk for both transporter and metabolic drug-
drug interactions is considered to be pronounced due to the higher drug 
concentrations that the transporters and metabolic enzymes face in the intestinal 
wall. Despite the extensive research on the area, the prediction of intestinal 
absorption taking into account also the many transporter and metabolism-related 
processes, has not been fully accomplished yet. That is mainly due to the lack of 
high quality data, generation of which requires appropriate use of the existing 
methods and development of new tools to complement the existing ones. 
This work focuses on the automatable microplate-based in vitro assays  that  are  
amenable to predicting the drug transport and metabolism in the intestine level. 
However, it should be noted that since most of the transporters and metabolizing 
enzymes discussed here are not expressed exclusively in human intestinal tissue, 
many of the assays are applicable in predicting the drug behaviour also in other 
tissues. 
During the course of this thesis work, a new high throughput screening tool for 
detecting compound interactions with one of the intestinal UGT isoforms (UGT1A6) 
was developed (I). The fluorescence-based assay is the first of a kind enabling the 
Introduction 
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direct determination of the probe reaction at the product site without separation or 
secondary reactions. The assay was also shown to be useful in providing data for 
computational model development (II).  The  resulting  classification  and  3D-QSAR  
models indicated physicochemical parameters and functional groups important to the 
compound interactions with the UGT1A6. Interactions of two drug compounds 
(indomethacin and diclofenac) with UGT1A6 were more thoroughly studied. The 
effect of pH on the interaction was examined in human liver and intestinal 
microsomes, as well as with an extensive set of individual recombinant UGT 
enzymes (III). The results indicated that the effects of pH were variable and enzyme 
specific. Finally, automation of fairly complex, but highly predictive intestinal in 
vitro transport models were studied in detail to further improve the utilization 




2 Review of the literature 
2.1 Intestinal drug absorption 
Human small intestine is approximately 5-6 m long tube having a highly folded 
surface structure (reviewed in Washington et al., 2001). Due to its special features, 
such as Kerckring valves, villus and microvillus (Fig. 1), the absorptive surface area 
is markedly higher than would be expected solely based on its length and diameter.  
 
Figure 1. Structure of human small intestine (Modified from Avdeef, 2001 and 
Thelen and Dressman, 2009, where in Hansen and Koepen, 2002). 
The enterocyte monolayer lining the intestinal wall is considered an important 
barrier for the oral drug absorption (Fig. 2) (reviewed in Chan et al., 2004). The 
processes affecting the drug absorption across the enterocyte monolayer are passive 
permeation (Fig. 2A), facilitated and efflux transport (Fig. 2B-2C) and intestinal 
metabolism (Fig. 2D), which may also co-operate with the efflux transport (Fig. 2E).  
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2.1.1 Passive permeation 
 
Passive diffusion across the enterocyte monolayer may occur either via transcellular 
or paracellular pathway (Fig. 2). Overall, the most important route for intestinal 
drugs absorption is the transcellular diffusion through the cells (reviewed in 
Lennernäs, 2007). In that process, the physicochemical properties of a drug mainly 
dictate how well it is partioned into and diffused through the apical membrane of the 
enterocytes (reviewed in Krämer et al., 1999 and Avdeef et al., 2001). According to 
the well-established “Lipinski´s Rule of 5”, compounds having molecular weight of 
higher than 500, logP of higher than 5, and more than 5 hydrogen bond donors or 
more than 10 hydrogen bond acceptors, are prone to be poorly absorbed (reviewed in 
Lipinski et al., 2001). 
The paracellular drug transport is efficiently hindered by tight junctions located 
between the cells. Therefore, the paracellular pathway may contribute to the 
transport of only small hydrophilic compounds, which are small enough to fit 
through the paracellular space, with pore radii of 7-13 Å (Fine et al., 1995, 
Linnankoski et al., 2010). Compounds utilizing this route are not subject to 
intracellular metabolism, which may be an advantage (reviewed in Thelen and 
Dressman, 2009). 
 
Figure 2. Drug absorption through the enterocyte monolayer may occur (A) 
passively either via trancellular or paracellular pathway. (B) Carriers, such as 
uptake transporters, may facilitate the transport of drugs that have low passive 
permeation. (C) Efflux transporters located on the luminal site of the monolayer 
are able to pump drugs back to the intestinal lumen, and thus restrict the 
absorption. (D) Efflux transporters may also participate in excretion of drug 
from blood circulation. (E) The panel of metabolic enzymes inside the 
enterocytes is capable of transforming the drug into metabolites that differ in 
their activity and toxicity from the parent compound. (F) Metabolism and efflux 
transporter may also co-operate (Modified from Chan et al., 2004). 
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2.1.2 Intestinal drug transport 
 
Several uptake and efflux transporters take part in the intestinal nutrient absorption 
as well as in preventing hazardous xenobiotics to enter the body or accumulate into 
the cells (Fig. 2) (reviewed in Chan et al., 2004; Szakács et al., 2008 and Oostendorp 
et al., 2009). Many of these uptake and efflux proteins have been reported to affect 
also the drug absorption, either by enhancing or inhibiting it.  
ABC  transporters  MDR1,  MRP2  and  BCRP  are  considered  the  main  efflux  
transporters on the apical membrane (reviewed in Higgins, 1992, Chan et al., 2004 
and Giacomini et al., 2010). They pump drugs back to the intestinal lumen against 
the concentration gradient by utilizing the energy released in ATP hydrolysis. 
Substrate and inhibitor specificities of these efflux transporters are broad and 
overlapping, but not equal. Many widely used cardioactive and anticancer drugs, as 
well as antivirals, antibiotics, antihypertensives and corticosteroids and their 
metabolites, among others, are either substrates or inhibitors of these efflux 
transporters. 
In contrast to the ABC transporters, apical SLCs, such as OATPs, PEPT1, ASBT 
and MCT1, may facilitate the absorption of drugs that structurally resemble their 
natural substrates (reviewed in Zhang et al., 2002, Klaassen and Aleksunes, 2010 
and Varma et al., 2010). The facilitated diffusion via a transporter follows the 
concentration gradient of the compound and is coupled with the flow of H+ and/or 
Na+ ions across the cell membrane. The function of at least OATP2B1, PEPT1 and 
MCT1 is pH dependent (reviewed in Anderson and Thwaites, 2010). The affinities 
of  substrates  to  PEPT1  and  MCT1  are  generally  low,  from  micro-  to  millimolar  
range, but transporting capacities are high, whereas the opposite applies to intestinal 
OATPs (reviewed in Varma et al., 2010). Drugs transported across the apical cell 
membrane by the intestinal OATPs, PEPT1 and MCT1 include statins (e.g 
atorvastatin), -lactam antibiotics (e.g. cephalexin) and carboxylic acids (e.g. 
valproic acid), respectively (Tamai et al., 1999; reviewed in Brandsch et al., 2008 
and Kalliokoski and Niemi, 2009). Whereas, ASBT is considered more a potential 
target for future prodrugs (reviewed in Balakrishnan and Polli, 2006) 
The transporters located on the basolateral membrane are less thoroughly studied. 
The ABC transporter MRP3 is considered to take part in the enterohepatic 
recirculation of bile acids, as well as in protecting the enterocytes against some 
organic anions, such as anticancer drugs (reviewed in Borst and Elferink, 2002), 
whereas solute carrier OCT1 is involved in intestinal secretion of e.g. metformin and 
quinidine (reviewed in Jonker and Shinkel, 2004). In addition, OST  and OST  are 
known to have an important role in the reabsorption of bile acids and steroid 
derivatives (Ballatori et al 2005). 
2.1.3 Intestinal drug metabolism 
 
In addition to and together with the active efflux, intestinal metabolism may 
substantially lower the bioavailability of orally administered drugs (Fig. 2) (reviewed 
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in Suzuki and Sugiyama, 2000). Even though the total metabolizing capacity of the 
intestinal tissue may be lower compared to that of liver, mainly due to the smaller 
size of the epithelial tissue, intestine is an important contributor to the first pass 
metabolism of drugs (reviewed in Lin et al., 1999, Kaminsky and Zhang, 2003 and 
Thelen and Dressman, 2009).  
CYPs are the major players in phase I oxidative drug metabolism in the small 
intestinal epithelium; CYP3A contributing 82% and CYP2C 16% of the intestinal 
CYP expression (Paine et al., 2006). They are located in the endoplasmic reticulum 
of the enterocytes in conjunction with NADPH-cytochrome P450 reductase, which 
provides the electrons for the CYP, and thus enables the oxygenation of the substrate 
(reviewed in Nebert and Gonzales, 1987 and de Montellano, 1999).  
Several enzymes responsible for phase II conjugation reactions, such UGTs 
(Peters et al., 1991; Ohno and Nakajin, 2009; reviewed in King et al., 2000 and 
Gregory et al., 2004) and SULTs (Chen et al 2003; Riches et al 2009), are expressed 
and functional in the intestinal wall. Of UGTs, isoform 1A1 is the most active in the 
intestinal level (Fisher et al., 2000); activities even higher than in the liver have been 
reported. In addition, the highest SULT expression levels have been detected from 
intestine, where SULT1B1 and SULT1A3 both accounted for about one third of the 
total SULT expression (Riches et al., 2009).  
The conjugation reactions aim primarily at inactivation and/or detoxification of 
the compound or its metabolite by adding a hydrophilic residue to the parent 
compound. The increased water solubility also results in an impoved excretion. 
However, there are examples of metabolites that are pharmacologically more active 
than the parent compound, e.g. morphine-6-glucuronide (Osborne et al., 1990), or 
more toxic like the reactive acyl glucuronides (Williams et al., 1992) or the sulfate 
conjugate of troglitazone (Saha et al., 2010).  
The  major  contributors  in  the  phase  II  metabolism,  the  UGTs,  catalyze  the  
addition of a sugar residue into a substrate having a nucleophilic functional group, 
most often a hydroxyl, a carboxylic acid or an amine (reviewed in King et al., 2000). 
The most abundant UGT subfamilies in humans are 1A and 2B, which utilize the 
glycosyl group from a co-substrate UDPGA to form a glucuronidated substrate ( -D-
glycopyranosiduronic acid conjugate). As a co-product, also UDP is formed. 
According to the common understanding, the UGTs are localized in the inner 
membrane of the ER, and therefore the substrates need to first pass through the ER 
membrane before getting in contact with the enzyme (King et al., 2000 where in 
Tephly and Burchell, 1990).  
In  addition  to  the  above  mentioned  phase  I  and  II  enzymes,  also  expression  of  
glutathione S-transferases (GSTs) (Peters et al., 1991; Coles et al 2002), alcohol, 
aldehyde and NAD(P)H dehydrogenases, epoxide hydroxylases, esterases, 
monoamine oxidases, acetyl transferases, catechol-O-methyltransferases and 
acetylserotonin-O-methyltransferases, among several other enzymes, have been 





2.2 In vitro model systems for intestinal transport and 
metabolism  
Involvement of uptake and efflux transporters in drug absorption through the 
intestinal wall can be studied with in vitro model systems of varying complexity and 
equivalency to human intestinal wall. Each model system has its advantages and 
limitations, which should be carefully considered, when choosing the biological 
model  system  for  a  particular  assay  (Table  1).  The  same  applies  to  the  model  
systems for metabolism studies. In general, the cellular systems often represent the 
most complex and biologically equivalent structures, whereas the transporters 
reconstituted on artificial lipid membranes or recombinant enzymes separated from 
cellular environment do not possess many structural similarities to the human 
intestinal wall. However, these models are useful in providing mechanistic 
information on the possible transport and metabolism processes.  
 
Table 1.  Summary of advantages and limitations of in vitro model systems 
suitable for intestinal drug transport and metabolism screens. 
 Advantages Limitations References 
Cellular  
models 
      
Full cellular machinery 
Intact cell membrane 
Transporters and metabolizing 
enzymes present (more or 
less) 
Monolayer formation 





Barrier properties are not equal  
to human intestinal wall 
Difficult to miniaturize 
SOPs needed 
Transporter conformation and  
activity may differ depending 
on the host cell 
Ganapathy et al  
1995; Artursson et al 
1996b; van de 
Kerkhof et al, 2007; 







       
Can be derived from human or 
animal tissue 
Several metabolizing enzymes  
present 
Easy to use 




Lack of drug transporters 
Micromes are lacking the  
cytosolic enzymes 
Co-factors need to be added 
High variation in enzyme  
activity 
Enzyme expression dependent  
on the segment of intestine 
where extracted 
Enzyme activities lower than 
in vivo 
Freezing and thawing cycles  
reduce the enzyme activity 
van de Kerkhof et al,  
2007; Laine, 2008; 
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Table 1. Continued… 
 Advantages Limitations References 
Recombinant 
enzymes 
      
Can be used for reaction  
phenotyping without spesific 
substrates/inhibitors (only one 
enzyme) 
Can be used for screening  
metabolic stability or 
evaluation of inhibition 
potential 
Experimental conditions can  
be controlled tightly 
Effect of rare enzyme  
polyforms can be assayed 
HTS compatible 
Commercially available 
Easy and fast to use 
Relative contribution of  
enzymes in metabolism of a 
compound may be difficult to 
determine (only one enzyme)  
IC50 values may not be  
compatible with the values 
obtained with microsomes 
(often lower) 
Enzyme conformation / activity  
may be dependent on the batch 
and recombinant system 
Co-enzymes and co-factors may 
need to be added 
Gonzalez and  
Korzekwa, 1995; 
Radominska-Pandya 
et al, 2005; Tang et 
al, 2005; Kumar et 
al., 2006; Fujiwara 
et al, 2008; Miners 
et al, 2010; 








systems     
Involvement of a single  
transporter can be assayed 




Easy and fast to use  
Artificial system composed  
only of the  membrane and 
transporter(s) 
Laborious preparation  
procedures 
Membrane composition may  
affect the transporter function 
(reconstituted) 
Xia et al 2007; Jin  
and Di 2008; 
Heged s et al 2009  
 
2.2.1 Cellular models 
 
Both primary enterocytes of animal and human origin (e.g. Hansen et al., 2000; 
Glaeser et al., 2002) and several cell lines (Table 2) can be used in studying the 
involvement of intestinal transporters and/or metabolism in drug absorption. 
However, poor availability, varying quality, as well as laborious and error-prone 
separation techniques of primary enterocytes limit their use (Weiser, 1973; Zhang et 
al., 1999b; Glaeser et al., 2002). Therefore, continuous cell lines presented in Table 2 
are often preferred.  
Caco-2 is the best characterized and the most widely used cell line for studying 
mechanisms of intestinal drug absorption (e.g. Pinto et al., 1983; Hidalgo et al., 
1989; reviewed in Artursson et al., 1996b). Even though derived from colon cancer, 
it polarizes and differentiates into a cell monolayer resembling that of the intestinal 
epithelia when cultured in vitro on  a  permeable  membrane  for  three  weeks.  It  has  
tight junctions and microvillus structure closely resembling that of the mature 
enterocytes.  In  addition,  several  transporters,  such  as  MDR1,  MRP2-3,  BCRP  and  
PEPT1 (Hunter et al., 1993; Augustijns et al., 1993; Taipalensuu et al., 2001; Seithel 
et al., 2006), and intestinal metabolizing enzymes, including UGTs (Abid et al., 
1995; Siissalo et al., 2008; Zhang et al., 2011), GSTs (Peters and Roelofs, 1989), 
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SULTs (Meinl et al., 2008) and esterases (Imai et al., 2005), are expressed and 
functional also in the differentiated Caco-2 model. However, the expression levels of 
these transporters and enzymes often differ from that in human duodenum 
(Taipalensuu et al., 2001; Sun et al., 2002; Seithel et al 2006; Zhang et al., 2011).  In 
particular, it is important to note that the expression levels of CYP enzymes in these 
cells are low, making this cellular model not suitable for studying intestinal CYP-
mediated metabolism. Furthermore, the properties of the cell line vary remarkably 
lab-to-lab, which highlights the need for using known marker compounds for 
standardizing the Caco-2 system in use (Hayeshi et al., 2008; reviewed in Artursson 
et al., 1996b).  
Table 2. Cell lines used for evaluating the role of intestinal drug transporters and 
metabolic enzymes in drug absorption.  









Resambles the most the intestinal  
epithelia, FDA recommended* 
*bidirectional transport, uptake and 
efflux assays 
Artursson et al.,  











Suitable for transfection, fast 
differentiation, FDA recommended* 
*bidirectional transport, uptake and 
efflux assays 












Suitable for transfection, fast  
differentiation, FDA approved* 
*bidirectional transport, uptake and 
efflux assays 
Adachi et al.,  





chinese hamster ovary 
 
Suitable for transfection 
uptake and efflux assays 








efflux transporter and CYP3A4 
induction assays 
Pfrunder et al.,  
2003; Hartley et 
al., 2006;  
Caco-2/TC7 Caco-2 subclone Higher CYP and UGT activities than  
in parent Caco-2 
Alternative for parent Caco-2 cells. 
Potential for studying simultaneously 
both transport and metabolism? 




Human recombinant DNA technologies have been utilized in tailoring the 
cellular models to better resemble the intestinal wall. For example, increased 
expression of CYP3A4, MDR1 or PEPT1 in transfected Caco-2 cells has been 
reported (Crespi et al., 1996; Han et al., 1998; Brimer et al., 2000). However, most 
commonly these techniques are utilized in developing cell lines that overexpress one 
or  few transporters  and/or  metabolic  enzymes.  That  kind  of  cell  lines  are  useful  in  
defining whether or not a certain transporter or metabolizing enzyme is involved in 
the transport and/or metabolism of a compound. One of the cell lines for this purpose 
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is  MDCK  (Cho  et  al.,  1989).  MDCK  II  clones  transfected  with  one  single  
transporter, e.g. MDCKII-MDR1, are most commonly utilized (Lowes and 
Simmons, 2002), but also double- (MDCKII-OCT1/MDR1) and triple-transfected 
(MDCKII-OATP1B1/  UGT1A1/MRP2)  MDCKIIs  have  been  reported  (Nies  et  al.,  
2008; Fahrmayr et al., 2011). Also LLC-PK1 and CHO cell lines have been shown to 
be suitable for transfection purposes (Covitz et al., 1996; Brimer et al., 2000; Adachi 
et al., 2003). 
2.2.2 Intestinal microsomes and S9 fraction 
 
Human intestinal microsomes (HIM) are prepared by differential centrifugation from 
homogenized human enterocytes (Paine et al., 1997; Zhang et al., 1999b). High 
quality intestinal microsomes have turned out to be more difficult to prepare than 
liver microsomes. Variation in the enzymatic activity is considered to be mainly due 
to the differences in experimental procedures used, e.g. the metabolizing enzymes in 
the cells may be damaged during the detachment procedure and exposed to 
proteolytic enzymes (Galetin and Houston, 2006). That can be minimized by adding 
protease inbitors to the elution media (Zhang et al., 1999b). Similar to liver 
microsomes, intestinal microsomes contain all the enzymes bound to ER membrane, 
such as CYPs and UGTs, but not the cytosolic ones, such as SULTs. Whereas S9 
fraction, the supernatant separated by centrifugation of the lyzed tissue or cells at 
9750g, contains both the microsomal and sytosolic enzymes (Sohlenius-Sternbeck 
and Orzechowski, 2004). As the expression levels of transporters and metabolizing 
enzymes differ along the intestinal track (Sun et al., 2002), the segment of the 
intestine where the cells used to prepare the microsomes and S9 fraction have been 
extracted from, is of great importance. 
Despite the challenges related to preparation, HIMs have been successfully used 
for assessing the intestinal CYP- and UGT-mediated first-pass metabolism (e.g. 
Sabolovic et al., 2004; Cubitt et al., 2009; Gertz et al., 2010). To lesser extent, also 
the intestinal S9 fraction has been utilized in studying the involvement of cytosolic 
enzymes, such as carboxyl esterases, in the intestinal metabolism of drugs (Ahmed et 
al., 1999; Yan et al., 2010).  
2.2.3 Recombinant enzymes 
 
Recombinant DNA technologies can be utilized to produce individual enzymes in 
suitable  host  cells,  which  have  low  or  no  inherent  expression  of  the  particular  
enzyme. Production of CYPs and UGTs by transient or stable transfection has been 
reported in several mammalian, bacteria and yeast cells, e.g. monkey kidney (COS) 
Chinese hamster lung fibroplast (V79) E. coli  and Sacharomyces cerevisae or 
Pichia Pastoris (reviewed in Crespi and Miller, 1999 and Radominska-Pandya et al., 
2005). In addition, high levels of CYPs and UGT enzymes can be expressed in 
baculovirus infected Spodoptera frugiperda (Sf9) insect cells (Buters et al., 1994; 
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Nguyen and Tukey, 1997; Kurkela et al., 2003). The recombinant enzymes are used 
either as purified proteins or, mainly in the case of membrane proteins, as a suitable 
membrane preparation, such as microsomes. 
In  the  case  of  CYPs,  also  the  amounts  of  their  electron  donor  partners,  such  as  
NADPH-P450 oxidoreductase and cytochrome b5,  affect  the  activity  of  the  
recombinant CYP enzymes (Shaw et al., 1997). These electron transfer partners may 
be expressed separately or as a fusion protein (Fisher et al., 1992; Rodriques et al., 
1995). The functionality of purified CYPs has been reported after purification from 
yeast and insect cells (Buters et al., 1994; Imaoka et al., 1996), whereas the activity 
of UGTs is easily lost upon extraction with detergents from the membrane (Kurkela 
et al., 2003), and therefore, the recombinant UGTs are used as membrane-bound 
protein preparations. 
2.2.4 Membrane vesicles and reconstituted transporter systems 
 
Membrane vesicles can be formed by disrupting cells in a buffer of low ionic 
strength in the absence of bivalent cations (Steck et al., 1970) or by nitrogen 
cavitation (Loe et al., 1996). As a result, a mixture containing membrane lamellae 
and vesicles of inside-out and right side-out orientation are formed. Most often, the 
membrane preparations are used as a mixture, but the relative amount of inside-out 
vesicles in the mixture can be increased by a special centrifugation procedure (Meier 
et al., 1984). Biological membranes containing transporters, such as intestinal brush 
border membranes (Murer et al., 1974) or cells genetically engineered to over-
express a particular transporter (Sarkadi et al., 1992; Lechner et al., 2010), can be 
used as a source material. However, membrane vesicles prepared from original 
human or animal tissue have often several different transporters embedded in the 
membrane, which complicates the interpretation of the transport mechanism in these 
vesicles. In addition, the presence of three types of membrane systems in the 
preparation further complicates the studies with more than one compound at a time. 
Vesicles are mainly used for studying compound interactions with the ATP-
dependent efflux transporters, and therefore, preferred orientation is inside-out. That 
enables monitoring the ATPase activity on the surface of the vesicles (Sarkadi et al., 
1992; Bakos et al., 1998), as well as uptake and accumulation studies with the efflux 
transporters (Horio et al., 1988). 
Transporters can be also reconstituted into lipid bilayers of artificially prepared 
membrane vesicles. The purified transporter can be inserted into a liposome 
membrane by first mixing the detergent-solubilized transporters with detergent-
destabilized liposomes, and then removing the detergents e.g. by adsorption to 
polystyrene beads (Geertsma et al., 2008). Liposomes composed of several different 
mixtures of synthetic phospholipids, such as dimyristoyl-phosphatidylcholine and 1-
palmitoyl-2-phosphatidylcholine (Lu et al., 2001), egg yolk L- -phosphatidylcholine 
and L- - phosphatide with cholesterol (Jacobs et al., 2011), soybean phospholipids 
together with phosphatidylserine and cholesterol (Borgnia et al., 1996) and lipid 
extracts of bovine brain (Bucher et al., 2007) or E. coli –bacteria (Newman and 
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Wilson, 1980; Geertsma et al., 2008) have been successfully utilized as membrane 
support for the intestinal ABC-transporters. Studies with liposomes prepared of egg-
phosphatidylcholine in the absence and presence of cholesterol revealed the 
importance of cholesterol, or structurally similar compounds, to the function of 






































2.3 Intestinal transporter assays 
In vitro assays that are widely used for screening the involvement of transporter(s) in 
intestinal drug absorption can be divided into three categories: 1) assays detecting 
the function of an ABC-transporter indirectly by measuring ATPase activity 
(ATPase assay), 2) assays following the uptake or accumulation of a compound into 
cells or vesicles, (uptake, accumulation and efflux assays), and 3) assays measuring 
the passage of a compound across a cell monolayer that resembles the intestinal 
epithelia (bidirectional transport assay). 
2.3.1 ATPase assay  
 
Energy required for the function of ABC-transporters is released in an ATPase 
catalysed cleavage of ATP. Detection of that reaction, either by detecting the 
liberation  of  organic  phosphate,  formation  of  ADP  or  consumption  of  ATP,  forms  
the basis for ATPase assays (Fig. 3) (Sarkadi et al., 1992; Garrigues et al., 2002; Ma 
and Cali, 2007). Several assay kits based on the above mentioned principles are also 
commercially available. 
Experimentally, the ATPase assay is the most straightforward of the in vitro 
transport assays. Compound(s) are simply incubated with the membrane preparation, 
either inside-out vesicles, open membrane lamellae or reconstituted transporters 
system, in the presence of MgATP, and the resulting absorbance or luminescence is 
recorded at the end (Sarkadi et al., 1992; Borgnia et al., 1996; Garrigues et al., 2002; 
Ma and Cali, 2007). The assay can be performed either in stimulation mode by 
detecting the increase in ATPase activity due to the compound transport or in 
inhibition mode by following the decrease in e.g. verapamil stimulated ATPase 
activity. Often inhibitors for non-ABC transporters, such as ouabain, sodium azide 
and EGTA, are added to the incubation buffer to minimize the contribution of other 
ATPase linked reactions. Results are usually reported as vanadate-sensitive ATPase 
activity representing the compound-related ATPase activation that can be inhibited 
by sodium orthovanadate. 
 
Figure 3. Assay principle of ATPase assay in inside-out membrane vesicles. 
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ATPase assay has been successfully used in defining compound interactions with 
MDR1, MRPs and BCRP (e.g. Litman et al., 1997a; Garrigues et al., 2002; Lespine 
et al., 2006; Glavinas et al., 2007; Holland et al., 2008). Compounds stimulating the 
ATPase activity are generally considered to be substrates of the particular transporter 
and those inhiting the stimulated activity either substrates or inhibitors. However, it 
should  be  kept  in  mind  that  ATPase  is  an  indirect  assay  and  does  not  measure  the  
compound transport itself. Therefore, the results should be considered suggestive, 
rather than decisive (Polli et al., 2001; Scwab et al., 2003). 
Several compound properties may impair the results. Especially, results obtained 
with compounds having extremely low or high passive membrane permeability, 
should be treated with caution (Polli et al., 2001; Scwab et al., 2003). The low 
permeability compounds may not be able to partition into the membrane at high 
enough concentrations to produce detectable ATPase conversion, even though they 
were substrates of a transporter, and the transporter would markedly impair their 
already poor absorption. With high permeability compounds the situation is 
opposite. In addition, high lipophilicity of a compound may lead to nonspecific 
binding, and decrease the effective compound concentration in the assay. 
Furthermore, test compounds may also interfere with the detection of inorganic 
phosphate liberation (Shirasaka et al., 2006).  
2.3.2 Uptake, accumulation and efflux assays 
 
Compound uptake and accumulation into membrane vesicles and cells or efflux from 
the cells allows the identification of substrates and inhibitors of a particular 
transporter (e.g. Horio et al., 1988; Holló et al., 1994; Vaidyanathan and Walle, 
2003; Lohman et al., 2007; Zhang et al., 2007; Siissalo et al., 2009). They also 
provide useful information of drug-drug interaction potential. Such assays can be 
performed either by following the uptake and accumulation of a compound into the 
vesicles or cells (direct mode), or by following the effect of a test compound on the 
uptake and accumulation or efflux of a suitable reporter substrate (indirect mode).  
In the direct assay mode, the compounds are incubated with the transporter 
system, either vesicles or cells, and after a specified time, the transporter function is 
terminated by the addition of ice-cold buffer (Horio et al., 1988; Bakos et al., 1998; 
Vaidyanathan and Walle, 2003; Zhang et al., 2007). Vesicles are then collected on 
filter (rapid filtration technique) and washed to remove the compounds that are 
bound nonspecifically to the external surface of the vesicles. In the cases of 
radiolabelled or fluorescent compounds, the amount of compound accumulated into 
the vesicles can be determined by quantifying the radioactivity in the filter (Horio et 
al., 1988). Also scintillation proximity assay technologies have been utilized in the 
detection of compound uptake into the tranporter-overexpressing cells (Lohmann et 
al., 2007). In cellular uptake assays, the cells are usually lysed after the stoppage of 
transporter function and prior to the compound analysis (Vaidyanathan and Walle, 
2003). If radiolabelled compounds are not available, compound concentration inside 
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the  cells  or  vesicles  can  be  quantified  with  UV-detector  after  HPLC  separation  
(Vaidyanathan and Walle, 2003) or with LC-MS/MS system (Putnam et al., 2002). 
Indirect uptake, accumulation and efflux assays utilize known substrates as 
reporter compounds. Calcein-AM assay is a widely utilized indirect assay that can be 
used for identifying compounds interacting with MDR1 (Holló et al., 1994; Eneroth 
et al., 2001; Crivori et al., 2006). The assay relies on the high passive permeation of 
calcein-AM through the cell membrane and its subsequent hydrolysis by intracellular 
esterases (Fig. 4). That reaction yields hydrophilic and highly fluorescent calcein, 
which cannot permeate the cell membrane passively, or be transported by the 
MDR1.  Inhibition  of  the  calcein-AM  efflux  is  detected  as  the  accumulation  of  
calcein into the cells, and thus, as fluorescence increase. In another commonly used 
approach, cells are loaded with a compound that is not a substrate for the particular 
transporter, but can passively permeate the cell membrane. Inside the cell the 
compound is transformed into a hydrophilic substrate that can escape the cell only 
via the transporter. One such substrate is a fluorescein derivative CDCFDA, a 
substrate for MRP2, which is hydrolysed to fluorescent CDCF inside the cells 
(Siissalo et al., 2009). The interaction of compounds with MRP2 can be detected as a 
lowered level of CDCF, and thus fluorescence, in the buffer.  
In principle, also many other good transporter substrates can be used as probes, if 
their passive permeation through the membrane is low enough to avoid leakage 
through the membrane during the assay. For example, rhodamine 123 is a commonly 
used reporter substrate in MDR1 cellular uptake assays (Perloff et al., 2003), and 
PhA has been successfully used with BCRP (Henrich et al., 2006). However, the 
probe should be carefully considered, since the choice of the probe substrate has 
been demonstrated to affect the results, as is discussed in more detail under the 
chapter 2.3.3 Bidirectional monolayer transport assay.  
 
 
Figure 4. Assay principle of Calcein AM assay (Modified from Kerns and Di, 
2008). 
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The assay conditions should be optimized for each combination of the transporter 
and biological model system, taking into account the properties and requirements of 
both. For example, in vesicular transport assays with ATP-dependent transporters, 
care must be taken to ensure sufficient amounts of ATP during the assay. If needed, 
ATP-regenerating system, creatine phosphokinase together with creatine phosphate, 
may be added to the system (Hirouchi et al., 2004). On the other hand, in the case of 
PEPT1, pH dependency should be considered, namely by providing a H+ gradient in 
the experimental setting, e.g. by performing the assays in a slightly acidic buffer 
(Ganapathy and Leibach, 1983; Vig et al., 2006).  
The observed uptake, accumulation or efflux of a compound is a combined result 
of both passive diffusion through the membrane and transporter-mediated passage. 
Therefore, care should be always taken to define also the non-transporter related 
transport, and subtract that from the observed total transport (e.g. Bakos et al., 1998). 
In the case of ATP-dependent transporters, vesicular uptake assay performed with 
AMP instead of ATP, or just without ATP, can be used to define the non-transporter 
related  uptake  (Bakos  et  al.,  1998),  whereas  the  experiments  at  pH  7.4  are  
appropriate for defining the PEPT1 unrelated transport (Ganapathy and Leibach, 
1983). Also inhibitors of particular transporters may be utilized in defining the extent 
of passive permeation (Scow et al., 2011). That is useful especially in the cases of 
cells expressing several transporters. 
 In uptake, accumulation and efflux assays, many compound properties may 
affect the reliability of the results. Highly lipophilic compounds may show false 
negative results (Polli 2001). Compounds may leak through the membrane or non-
specifically bind to the membrane, and thus, the accumulation of compounds inside 
the vesicles or cells may be underestimated. Also compounds having a very low 
membrane permeability may not be able to partition into the membrane at high 
enough concentration and compete with the MDR1 probe substrates. In addition, in 
the cellular uptake assays, toxicity issues should be considered to reduce the risk of 
false negatives and positives due to the cellular damage. 
2.3.3 Bidirectional monolayer transport assay 
 
Comparison of apparent permeability, Papp –values, or flux, of a compound across a 
cell  monolayer  in  absorptive  (A-B,  apical  to  basolateral)  and  secretive  (B-A,  
basolateral to apical) directions provides useful information on the involvement of 
efflux or uptake transporter(s) in drug absorption (e.g. Inui et al., 1992; Augustijns et 
al., 1993; reviewed in Artursson et al., 1996a; Hubatsch et al., 2007). Most 
commonly, and also recommended by the FDA for identifying substrates and 
inhibitors for MDR1, bidirectional monolayer transport assays are performed across 
Caco-2 or transporter overexpressing MDCKII or LLC-PK1 monolayers (Adachi et 
al., 2001; Tang et al., 2002; reviewed in Zhang et al., 2006; FDA, 2006).  
In practice, a monolayer transport assay is performed by adding the compound(s) 
of interest either to the apical or basolateral compartment, and by detecting the 
appearance on the opposite site of the monolayer (Fig. 5) (reviewed in Artursson et 
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al., 1996a; Hubatsch et al., 2007). The analysis of the samples is usually carried out 
either by HPLC with UV or fluorescence detector or by LC-MS/MS (e.g. Inui et al., 
1992; Wang et al., 2000). In the case of fluorescent or radiolabelled compounds, also 
fluorescence plate reader and liquid scintillation counting can be utilized (Tang et 
al., 2004; Xia et al., 2005). If the ratio (Papp B-A/Papp A-B)  with  Caco-2  cells  or  the  
difference of the ratios observed with transfected and wild type cells (ratiotransfected / 
ratiowild type) markedly deviate from one, a compound may be a substrate for an efflux 
or an uptake transporter(s) (e.g. Adachi et al., 2001; Tang et al., 2002). The 
involvement of transporter(s) may be further confirmed by performing the assay in 
the presence of inhibitors through a cell monolayer in which the expression level and 
functionality of transporters are well demonstrated (Augustijns et al., 1993; Hunter et 
al., 1993; Tang et al., 2002; Bjornsson et al., 2003; Xhang et al., 2006). For detecting 
inhibitors, the transport of a substrate can be followed in the presence and absence of 
the compound of interest (e.g. Fromm et al., 1999; Bjornsson et al., 2003; Zhang et 
al., 2006).  
To avoid erroneous results due to the leakage of the compound through possible 
gaps in the monolayer, TEER is usually measured before and after the assay 
(reviewed in Artursson et al., 1996a; Hubatsch et al., 2007). Also permeation of 
passive paracellular transport markers, such as [14C]-mannitol, is often monitored in 
parallel with the transport of the compound(s) of interest.  
 
Figure 5. Assay principle of the bi-directional transport assay (modified from Jin 
and Li, 2008). 
The choice of inhibitors and substrates for the assay is complicated by several 
factors. Firstly, the transporters may have several binding sites, as clearly 
demonstrated in the case of MDR1 (Ayesh et al., 1996; Litman et al 1997b; Shapiro 
and Ling, 1997; Martin et al., 2000). Secondly, many of the compounds are 
transported by or inhiting/modulating the function of more than one transporter. For 
example, vinblastine is transported by MDR1 and MRP2 (Horio et al., 1988; Evers 
et al., 2000) and GF120918 is an inhibitor for three different transporters, MDR1, 
BCRP  and  MRP2  (Matsson  et  al.,  2009).  Thirdly,  the  function  of  substrates  and  
inhitors may be dependent on the cellular system (van der Sandt et al., 2000; Wang 
et al., 2008b).  
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Of the MDR1 substrates, digoxin is usually the primary choice due to its 
selectivity towards MDR1 and applicability to both in vitro and in vivo drug 
interactions studies (Keogh and Kunta, 2006; Rautio et al., 2006). Also the use of 
vinblastine, colchicine and quinidine is well established (Taub 2005; Rautio et al., 
2006; Patil et al., 2011). In addition, rhodamine 123 and Hoechst 33342 can be used 
as probes for detecting the specific binding site within MDR1 (Tang et al., 2004). 
However, rhodamine 123 was shown to require carrier mediated influx for its 
activity as a MDR1 substrate in Caco-2 cells (Troutman and Thakker, 2003). 
Whereas, methotrexate and estrone-3-sulfate have been used as probe substrates for 
BCRP, although they are not specific substrates for BCRP (Xia et al., 2005). As for 
inhibitors, GF120918, verapamil, MK-571 (MDR1, BCRP, MRP2) and Ko143 
(BCRP, MRP2) are among the widely used inhibitors (Ozawa et al., 2004; Matsson 
et al., 2009).  
The main drawbacks related to the bidirectional transport assays are the long 
culturing time of the cells and the often laborious compound analysis. Attempts have 
been made to decrease the culturing time of the Caco-2 monolayer (Yamashita et al., 
2002; Alsenz and Haenel, 2003; Miret et al., 2004; Galkin et al., 2008). However, 
the transporter profiles have not been comparable to those of mature monolayers 
(Miret et al., 2004). Similar to metabolism assays, compound cocktail and sample 
pooling have been also suggested as means of more efficient sample analysis in the 
bidirectional Caco-2 transport assays (Bu et al., 2000; Hakala et al., 2003; Laitinen et 
al., 2003; Koljonen et al., 2006). 
Despite the challenges, the bidirectional monolayer transport assay is considered 
to be the most reliable microplate-based in vitro method for evaluating drug 
interaction potential occuring via the MDR1 (Polli et al., 2001; Schwab et al 2003; 
FDA, 2006). The assay may be unable to detect lipophilic substrates due to their 
high passive permeation through the membrane (Lenz et al., 2000; Polli et al., 2001). 
Nevertheless, this should not be a major issue, since in the case of lipophilic 



















2.4 Intestinal metabolism assays 
2.4.1 Metabolic (in)stability 
 
The metabolic stability of a drug is routinely assayed in vitro using subcellular liver 
fractions (microsomes, sytosolic, S9) to predict the metabolic first-pass clearance of 
a drug (reviewed in Jia and Liu, 2007). With increasing understanding on the 
contribution of the intestinal metabolism to the total first-pass metabolism of many 
orally administered drugs, interest in taking into account also the contribution of 
intestinal biotransformation on the total first-pass metabolism has increased (e.g. 
Thummel et al., 1996; Cubit et al., 2009). So far, the models and assays used for 
studying drug metabolism at the intestinal level are not as well validated and reliable 
as the ones routinely used for studying metabolism in liver. 
In intestinal level, metabolic stability, metabolite identification and reaction 
phenotyping can be assayed in the subcellular intestinal fractions, most often human 
intestinal  microsomes  (HIM),  but  also  with  the  S9  fractions  (e.g.  Thummel  et  al.,  
1996; Ahmed et al., 1999; Galetin and Houston, 2006; Cubit et al., 2009) and in 
individual recombinant enzymes (reviewed in Crespi and Miller, 1999 and in Tang et 
al., 2005). Subcellular fractions of animal intestine can be used to predict species 
differences (e.g. Mazur et al., 2010; Yan et al., 2010). In addition, enterocyte 
homogenates of human and intact enterocytes of animal origin have shown 
utilization potential (Glaeser et al., 2002; Bonnefille et al., 2011). 
The experimental set up of the metabolism assay depends on the enzyme source 
used. With subcellular fractions, reaction co-factors, such as NADPH for CYPs, 
UDPGA for UGTs, PAPS for SULTs and GSH for GSTs, need to be added, whereas 
in intact cells those co-factors are expected to be present inherently (reviewed in van 
de Kerkhof et al., 2007). With intestinal microsomes, the pore forming agent 
alamethicin increases the activity of UGTs, probably through increasing the access 
of UDPGA to the enxyme UDPGA binding site, inside the microsomes. 
Recombinant UGTs do not benefit markedly from alamethicin addition (Kemp et al., 
2002; Zhang et al., 2011), probably since the membrane preparations for the Sf9 
insect cells, where they reside, are already permeable for the UDPGA. Differences in 
sensitivity to organic solvents, such as DMSO, ethanol and methanol, have been 
noted for CYPs, whereas UGTs are commonly much less sensitive to this solvent 
(Busby et al., 1999; Uchaipichat et al., 2004; Zhang et al., 2011). Contrary to the 
prediction of metabolic clearance with liver microsomes, extent of plasma protein 
binding, measured rutinely in vitro as drug binding to bovine serum albumin, does 
not seem to have that important role in determining intestinal metabolic clearance 
during the intestinal drug absorption (Hall et al., 1999; Yang et al., 2007). 
Nevertheless,  the  addition  of  BSA to  remove  the  inhibitory  fatty  acids  that  bind  to  
some of the UGTs, probably during the microsome preparation, has recently shown 
to be highly beneficial (Rowland et al., 2008; Manesvki et al., 2011). In addition, 
acidic and basic assay conditions have been found to increase the glucuronidation of 
acidic and basic drugs, respectively (Chang et al., 2009). Furthermore, the extent of 
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nonspecific binding of drugs to microsomes has been found to be mainly dependent 
on the lipophilicity and the charge state of the drug (Soars et  al.,  2002; Gao et  al.,  
2008; Benoit-Biancamano et al., 2009).  
With each assay performed with subcellular fractions or recombinant enzymes, 
several control incubations are recommended, namely without the parent compound, 
without the co-substrate and without the enzyme source (reviewed in Jia and Liu, 
2007). In addition, incubations with microsomes prepared from untransfected cells 
or  membranes  of  cells  transfected  with  the  mock  virus,  can  also  serve  as  good  
controls, since they allow for taking into account the effect of inherent enzymatic 
processes in the host cell and drug binding to the membranes that carry the 
recombinant enzyme (e.g. Manevski et al., 2011). 
The analysis of either the parent compound or the formed metabolites is most 
often  performed,  with  appropriate  LC-MS  set  ups,  from  the  supernatant  of  the  
incubation mixture after protein precipitation and centrifugation (reviewed in Lahoz 
et al., 2008 and Tolonen et al., 2009). Acetonitrile, trichloroacetic acid and zinc as 
sulfate salt have shown to be efficient in precipitating proteins (Polson et al., 2003). 
Although LC-MS is considered the standard method in metabolite analysis due to the 
high sensitivity and decreasing analysis times, it may not be able to identify all the 
minor metabolites, the site within the parent compound, where the metabolic 
reaction has occurred, or to quantify the metabolites if the authentic metabolites are 
not available (reviewed in Liu and Jia, 2007). In addition, the outcome of the MS 
analysis is highly dependent on the instrument used (reviewed in Tolonen et al., 
2009). Microscale LC-MS combined with microdroplet NMR was lately reported 
(Lin et al., 2008), and perhaps future developments in the sensitivity and speed of 
NMR analysis will support the use of this technology also in routine metabolite 
identification. 
2.4.2 Metabolic inhibition and induction assays 
 
In vitro metabolic enzyme inhibition and induction assays provide important 
information on drug-drug interaction potential of a compound before in vivo 
experiments, and may also be used to further confirm the mechanism of inhibition or 
induction observed in vivo (reviewed in Jia and Liu, 2007). Many inhibition assays 
have also been succesfully miniaturized and are rutinely run in high density plate 
formats (e.g. Crespi et al., 1997; Moody et al., 1999; Trubetskoy et al., 2005; Larson 
et al., 2011; reviewed in Lahoz et al., 2006). Due to the important role of CYP(s) in 
drug metabolism, most effort has been put on developing assays for detecting the 
inhibitors and inducers for CYPs. However, assays are emerging also for other 
metabolic enzymes, e.g. UGTs, as the knowledge on their importance on drug 
metabolism is increasing.  
Inhibition of a metabolic enzyme in the intestine can be studied in vitro by 
following the effect of a compound on probe substrate metabolism in incubations 
with intestinal microsomes or recombinant enzymes (e.g. Gibbs et al., 1999; Zhang 
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et al., 2007). The experimental conditions discussed in chapter 2.4.1 Metabolic 
stability apply to the enzymatic inhitibition assays as well.  
Contrary to the inhibition assays, induction of enzyme expression can only be 
determined in intact cells that contain the nucleus and all the needed enzymes. The 
cell model LS180 was shown to be suitable for induction studies at the intestinal 
level (e.g.; Hartley et al., 2006; Harmsen et al., 2008; Fan et al., 2011). Typically, the 
cells are exposed to the compounds for 2-3 days, after which the metabolic activity 
of the enzyme is determined with an appropriate probe substrate or via reporter gene 
activity assay, and compared to the values of unexposured cells. In addition, changes 
in protein levels and mRNA levels give valuable information on the induction of 
gene expression (Cotreau et al., 2000; reviewed in Worboys and Carlile, 2001).  
The choice of a probe substrate is of great importance for inhibition and 
induction assays. Drug probes are considered to provide more in vivo relevant data 
than fluorescent or luminescent counterparts (Cohen et al., 2003; Bell et al., 2008). 
However, if not radiolabelled, the detection of most of the drug probe substrate 
metabolism requires LC-MS analysis, which is still, despite the recent advancements 
in LC-MS analysis (reviewed in Liang et al., 2011), more time-consuming than the 
detection of radiolabelled, fluorescent or luminescent probe reactions with simple 
plate readers. Properties of an ideal probe substrate for metabolic inhibition and 
induction assays are presented in Table 3.   
Thorough reviews on recommended probe substrates, inhibitors and inducers for 
CYPs are available (Tucker et al., 2001; Liu et al., 2007). Of the drug probes, 
midazolam and testosterone are considered the golden standards for CYP3A 
(Thummel et al., 1994; Obach et al., 2001), and diclofenac and S-mephenytoin for 
CYP2C9 and CYP2C19, respectively (Obach et al., 2001). Several nonspecific 
fluorescent probes, such as 3-cyano-7-ethoxycoumarin, resorufin benzyl ether 
(Crespi et al., 1997), 3-(3,4,-difluorobenzyloxy)-5,5-dimethyl-4-(4-methyl-
sulfonylphenyl)-5H-furan-2-one (Chauret et al., 1999), dibenzylfluorescein, 
benzyloxyresorufin (Stresser et al., 2000), 7-benzyloxyquinoline, 7-benzyloxy-4-
trifluoromethylcoumarin (Stresser et al., 2002) and Vivid® substrates (Trubetskoy et 
al 2005) have been succesfully used in high throughput CYP screens. In addition, 
assays utilizing proluminescent substrates have emerged for CYPs, offering less 
compound interference problems with the fluorescent compounds than the 
fluorescencent probes (reviewed in Cali et al., 2006). Proluminescent substrates have 
a common luciferin structure, which is then further modified with different 
functional groups to guide the substrate specificity. For example, different 
proluciferin acetals have been suggested as appropriate substrates for the CYPs 
(Meisenheimer et al., 2011). Fluorescence and luminescence-based assay kits for 
several CYPs are currently commercially available.  
For other intestinal metabolic enzymes, clear consensus on appropriate probe 
substrates have not been reached yet. Fluorescence- and luminescence-based assays 
exist also for the UGTs (Collier et al., 2000; Larson et al., 2011), and a luminescent 
assay is also commercially available.  
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Table 3. Properties of an ideal probe substrate in in vitro metabolic inhibition and 
induction assays. 
Property Reference 
Km of the substrate is in the same range as clinically relevant IC50 values 
Aqueous solubility of the substrate >> Km 
Unique single product is formed. 
Formation of product is detectable at 1% conversion 
Product is stable. It is not further metabolized or degraded under the assay  
conditions. 
No mechanism-based inactivation of the enzyme by the substrate. 
Saturable and monophasic kinetics. 
Absorbance, fluorescence or luminescence of the substrate and the product  
differ (if analysis by plate-reader is aimed) and the signal intensity is high 
enough to enable sensitive detection in aqeous solutions. 
Detection based on the appearance of the product rather than the disappearance  
of the probe substrate 
The higher the detection wavelength the less compound interference in likely to 
occur (absorbance, fluorescence). ex > 420 nm in CYP assays with fluorescent 
probe recommended to avoid photo damage. 
[S]  Km of the substrate can be used in the assay. 
The probe is selective towards the enzyme in question (subcelluar fractions). 
Feasible for both in vitro assays and in vivo studies. 
Substrate and metabolite(s) should be commercially available. 
Cohen et al., 2003 
Cohen et al., 2003 
Cohen et al., 2003 
Cohen et al., 2003 
Cohen et al., 2003 
 
Cohen et al., 2003 
Cohen et al., 2003 
Cohen et al., 2003;  
Meisenheimer et al., 
2011 
Tucker et al., 2001 
 
Cohen et al 2003;  
Simeonov et al., 2008 
 
Copeland et al., 2003 
Yuan et al., 2002 
Palmer et al., 2001 
 
 
Inhibition profiles of many metabolic enzymes have been reported to be substrate 
dependent (Kenworthy et al., 1999; Stresser et al., 2000; Wang et al., 2000). In the 
case of CYP3A4, the most thoroughly studied of the enzymes, this is considered to 
be due to the possibility of multiple substrates to bind to the enzyme simultaneously 
(e.g. Shou et al., 1994) or the non-Michaelis Menten kinetics that has been observed 
with many of the substrates (Kronbach et al., 1989, Ueng et al., 1997), including 
different inhibition modalities (reviewed in Zhang and Wong, 2005). Lately, 
multiple substrate binding with UGT2B7 (Uchaipichat et al., 2008) and substrate 
dependent inhibition profiles with CYP2D6 (VandenBrink et al., 2012) have also 
been observed. Therefore, when evaluating the drug interaction potential of a 
compound with the enzymes, especially with CYP3A, inhibition profiles towards 
several drug probes should be determined (Kenworthy et al., 1999; Wang et al., 







2.5 Automation of transport and metabolism assays 
In general, automation of in vitro assays increases throughput, decreases human 
errors and need for labour, releases working hours for more challenging tasks and 
improves safety issues (Banks et al., 1997).  
Both fully automated and semi-automated systems have been established for the 
transport and metabolism assays (e.g. Jenkins et al., 2004; Hugger et al., 2003). Fully 
automated systems are capable of performing full assay procedures, from the test 
compound  management  through  the  sample  preparation  and  sample  analysis,  until  
the data processing, unattended (Banks et al., 1997; reviewed by Saunders, 2004). 
Usually, they utilize a centralized robotic arm, which integrates several liquid 
handling stations, analytical devices, incubators and plate stackers to the system. 
These systems are best suited for high compound numbers assayed with fairly simple 
protocols. Whereas, semi-automated systems, comprising a single liquid handling 
workstation, are more flexible for manual interruptions and reprogramming, and 
therefore, usually used in executing sections of more challenging assay protocols 
(Sills et al., 1997; reviewed by Saunders, 2004). 
An ideal assay for automation would have simple, preferably add-mix-measure -
type of a homogenous assay protocol (reviewed in Bronson et al., 2001). Of the in 
vitro transport and metabolism assays used to predict these processes at intestinal 
level,  CYP  inhibition  and  ATPase  assays  fullfill  these  criteria  the  most  closely  
(Table 4). Today, automated CYP inhibition assays, which are based on probe 
reactions yielding fluorescent or luminescent signal in incubations with recombinant 
CYPs, are rutinely run both in 384-well (Kariv et al., 2001; Larson et al., 2011) and 
in 1536-well formats (Trubetskoy et al., 2005; Litten et al., 2010). Vesicular 
transport assays should also be adaptable to at least 384-well format, but information 
on the plate format routinely used is not publicly available. Also ATPase assay and 
the efflux assays based on PhA accumulation can be run at least in 384-well format 
(Garrigues et al., 2002; Henrich et al., 2006). All the other assays have not been 
reported at higher than 96-well format. Screening of metabolic instability in liver 
microsomes with LC-MS analysis of metabolites (e.g. Di et al., 2003; Jenkins et al., 
2004; McNaney et al., 2008), as well as calcein AM assay and bidirectional transport 
assays through both MDCK and Caco-2 cell monolayers (Eneroth et al., 2001; Xiao 
et al., 2006; Galkin et al., 2008) have been reported at 96-well format. Although no 
automated platforms have been reported so far for studying metabolic instability in 
intestinal microsomes, the assays validated for liver microsomes should be 
applicable with minor changes.  
In the future, ligand binding assays for nuclear receptors utilizing fast detection 
technologies (TR-FRET, SPA) (Hereley et al 2007; Wang et al 2008a; Shukla et al 
2009) and PEPT1 assays based on the measurement of the changes in electric current 
(Faria et al., 2004; Kelety et al., 2006) could serve as easily automatable higher 
throughput assay formats for screening the intestinal drug transport and metabolism. 
Similar to studying metabolism in liver, substrate cocktails taking into account the 
most important metabolic enzymes in the intestinal level would also be useful.  
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Table 4. Summary of assays used for screening intestinal drug transport and 
metabolism at 96- or higher well formats. 
Assay type Assay principle and detection technology Reference 
ABC transporters 
     ATPase assay 
     ATPase assay 
     ATPase assay 
     Uptake assay 
     Efflux assay 
     Efflux assay 
     Efflux assay 
     Bidirectional  
     transport assay 
     Bidirectional 
     transport assay 
SLC transporters 
     Uptake assay 
     Uptake assay 
 
Pi-molybdate complex  Absorbance 
NADH consumption  Absorbance 
ATP consumption  Luminescence  
Compound accumulation  LSC 
Calcein-AM accumulation  Fluorescence 
CDCF efflux  Fluorescence 
PhA accumulation  Fluorescence 
Compound transport across cell monolayer    
 LC or LC-MS/MS 
Compound transport across cell monolayer    
 Absorbance 
 
Radiolabelled substrate  LSC 
Radiolabelled compound SPA 
 
Sarkadi et al., 1992 
Garrigues et al., 2002 
Ma and Cali, 2007 
Tabas and Dantzig, 2002 
Holló et al., 1994 
Siissalo et al., 2009 
Henrich et al., 2006 
Xiao et al., 2006;  
Galkin et al., 2008 
Alsenz and Haenel, 2003 
 
 
Vig et al., 2006 
Lohmann et al., 2007 
Phase I metabolism 
     Metabolite screening 
     Inhibition assay 
     Inhibition assay  
     Inhibition assay 
     Inhibition assay 
     Inhibition assay 
     Inhibition assay 
 
Metabolite identification  LC-MS 
Drug probes  RapidFire LC-MS/MS 
Profluorescent substrate  Fluorescence 
Vivid® substrate  Fluorescence 
Proluciferin substrate  Luminescence 
Radiolabelled substrate  LSC 
Radiolabelled substrate  SPA 
 
Shou et al., 2005 
Miller, 2011 
Crespi et al., 1997 
Trubetskoy et al., 2005 
Cali et al., 2006 
Moody et al., 1999 
Delaporte et al., 2001 
Phase II metabolism 
     Glucuronidation assay 
     Glucuronidation assay 
     Inhibition assay 
     Inhibition assay 
 
     Inhibition assay 
     Inhibition assay 
     Inhibition assay 
 
Radiolabelled UDPGA  LSC 
Antibody-bound tracer/UDP  FP 
Proluciferin substrate  Luminescence 
Fluorescent substrate 
 
-glucuronidase  Fluorescence 
Proluciferin substrate  Luminescence 
Halogenated substrate  Absorbance 
 
Di Marco et al., 2005 
Kleman-Leyer et al., 2009 
Larson et al., 2011 
Collier et al., 2000; 
Trubetskoy et al., 2007 
Trubetskoyand Shaw, 1999 
Yasgar et al., 2010 
Skopelitou and Labrou,  
2010 
 
Several issues need to be considered when assays are set up on liquid handling 
workstations (Table 5). The precise and accurate liquid handling is the key issue in 
assay quality, but on the other hand, the assay throughput should not be too much 
affected. Contaminations should be carefully detected and minimized by choosing 
the most appropriate tips and liquid handling settings for each chemical. Whereas, 
the mixing efficiency is dependent on the correct combination of liquid volume and 
 
25 
method used. When working with transporters and metabolic enzymes, it must be 
remembered that too vigorous stirring may cause degradation and impair the 
functionality of the proteins. Evaporation of liquids may become a problem during 
prolonged incubations, if the plates cannot be sealed. The transport and metabolism 
studies are normally run at +37ºC, which promotes the evaporation. In addition, the 
assay volume determines the plate format and the choice of liquid handling device. 
Today, automated liquid handling devices capable of dispensing liquids at micro-, 
nano- and picoliter scale are available (reviewed in Hong et al., 2009; Arrabito and 
Pignataro, 2010). So far, most of the microplate-based transport and metabolism 
assays are mainly run in microliter scale as they are performed in no higher than 
384-format (Table 4). However, nanoliter scale liquid dispensing may be useful in 
the assays run at 1536-well format. 
 
Table 5. Issues to be considered when setting up in vitro assays on an automated 
liquid handling workstation. 
Issue Factors affecting Reference(s) 
















Liquid handling settings (speed, height, extra volumes)  
Single dispense vs multidispense 
Fixed vs disposable tips 
Liquid properties (e.g. foaming, dripping) 
Detection method (gravimetric or colorimetric) 
Single vs multidispense  
Single vs multitip system up to 384 tips 
Fixed tips cleaning (carry-over) 
Disposable tip quality (leachables) 
Liquid properties (e.g. volatile, dripping) 
Liquid volume 
Method (orbital shaker, magnetic stirrer, ultrasound, 
organic solvent drop) 
 
Liquid volume 
Sealed or open plate 
Incubation time 
Temperature 
Berg et al., 2001; 
Taylor et al 2002; 
Frégeau et al 2007; 




Astle and Acowitz,  
1996; Maddox et al., 
2008 
Berg et al., 2001; 
V&P Scientific Inc; 
Oldenburg et al., 2005 
Mitre et al., 2007 
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3 Aims of the study 
The importance of several drug transporters and metabolizing enzymes on the 
overall intestinal drug absorption of many drugs is well known. In order to be able to 
predict the involvement of the transporters and metabolizing enzymes in drug 
absorption at the different stages of drug discovery, in vitro tools of varying 
complexity and predictivity are needed.  
 
The more specific aims of the thesis work were: 
 
1. To develop a fluorescence-based high throughput screening assay for 
detecting drug interactions with UGT1A6 (I). 
 
2. To utilize the UGT1A6 screen to provide data for developing 
computational models for predicting the compound interactions with 
the UGT1A6 (I, II). 
 
3. To further evaluate the effects of pH on the interactions of model 
drugs, diclofenac and indomethacin, with the human UDP-
glucuronosyltransferases (III). 
 
4. To test the feasibility of three different types of cell-based assays on a 
robotic workstation, to address the critical liquid handling parameters 
in each assay, and to evaluate the factors affecting the ease and 











Antipyrine (IV), atenolol (IV), doxorubicin hydrochloride (IV), 5-fluorouracil (IV), 
(±)metoprolol tartrate (IV), hydrochlorthiazide (IV),  nadolol  (IV), -propranolol 
(IV), ranitidine hydrochloride (IV), fluorescein sodium (IV), 1-naphthol (I, II, III), 
1-naphthylglucuronide (1-NG) (I, III), 4-methylumbelliferone (III), 4-
methylumbelliferone glucuronide (III), 5-methylsalicylic acid (I, II), 
5-bromosalicylic acid (I, II), 5-chlorosalicylic acid (I, II), 5-fluorosalicylic acid (I, 
II), sodium salicylate (I, II), diclofenac sodium (I, II, III), indomethacin (II, III), 
naproxen (II, III) and scopoletin (I, II) were purchased from Sigma-Aldrich Chemie 
(Steinheim, Germany). Vinblastine sulphate (IV) and rhodamine 123 (IV) were from 
Fluka Chemie (Buchs, CH), ketoprofen (II, IV) from MP Biochemicals LLC 
(Aurora, OH) and carbamazepine (IV) from Hawkins, Inc. (Minneapolis, MN). 
Dexibuprofen (I, II) was from Sekhsaria Chemicals Limited (Thane, India), 
ibuprofen (I, II) from Francis s.p.a. (Italy) and 4-hydroxyindole (I, II) from TCI 
Europe (Zwijndrecht, Belgium). D-[1-14C]-mannitol (specific activity 59 mCi/mmol) 
(IV) was purchased from Amersham Pharmacia Biotech UK Ltd. (Amersham, 
England) and [3H(G)]-digoxin (specific activity 21.8 Ci/mmol) (IV) from 
PerkinElmer (Boston, MA). 
The Caspase-Glo® 3/7  assay  kit  (IV) was provided by Promega Corporation 
(Madison,  WI).  The  tetra-His  antibodies,  from  QIAGEN  (Hilden,  Germany),  were  
used to determine the relative expression levels of the individual recombinant UGTs 
(Kurkela et al., 2007). All the solvents were HPLC grade.  
4.2 Model systems 
Recombinant  human  UGTs  (I, III, IV), all except UGT2B15, were expressed in 
baculovirus-infected insect cells, as previously reported (Kurkela et al., 2003; Sneitz 
et al., 2009). Recombinant UGT2B15 “supersomes”, human liver microsomes and 
human intestinal microsomes were from BD Biosciences (Franklin Lakes, NJ, USA) 
(III).  
The colon carcinoma cell line Caco-2 was originally from the ATCC (Rockville, 
MD) and the prostate cancer cell line DU-145 was a generous gift from the Medical 
Biotechnology Department of Technical Research Center of Finland (VTT Turku). 
They were both cultured for the experiments as reported in original publication IV. 
4.3 TECAN workstation 
The assays (I, II, IV) were automated on a TECAN Genesis RSP 150/8 workstation 
(TECAN Schweiz AG, Männedorf, Switzerland) equipped with a Liquid Handling 
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Arm  and  a  Robotic  Manipulator  Arm.  Gemini  3.4  (TECAN  software  GmbH,  
Hannover, Germany) and FACTS (Flexible Assay Composer and Task Scheduler) 
4.81 (TECAN Schweiz AG) softwares were used to generate and operate the 
pipetting scripts and assay protocols. Pipetting precision was assessed using 
colorimetric methods as described in original publication IV. 
4.4 Assay protocols 
4.4.1 Automated HTS assay for UGT1A6 (I, II) 
 
The reaction mixture consisted of, if not otherwise specified, 50 mM phosphate 
buffer (pH 7.4), 10 mM MgCl2, 1-100 µg/ml of protein (insect cell membranes that 
contained the recombinant UGT1A6) and 2 mM UDPGA, in milli-Q water 
(resistance 18.2 M cm-1). The aglycone substrate 1-naphthol was used as the probe. 
Also artifact samples, 2.5 µM of 1-naphthylglucuronide (1-NG) in reaction mixture 
with and without investigational compound, were run to detect and enable correction 
of possible compoud interference with 1-NG signal detection. More detailed HTS 
protocol is presented in Figure 6. 
 
Figure 6. The UGT1A6 screening assay was initiated by delivering the compounds 
(step 1) and reaction mixture (step 2) into the test plate, after which the plate 
was preincubated (step 3). The reactions were initiated by UDPGA addition 
(step 4). The fluorescence was recorded immediately after the initiation (step 5) 
and after 30 min incubation (steps 6-7). 
4.4.2 Inhibition of 1-naphthol glucuronidation (I, III) 
 
Glucuronidation reactions were performed similarly to those done in the HTS assay, 
with the exceptions that the reactions were carried out in 1.5 ml tubes, stopped by 
adding 10 µl of ice-cold 4 M perchloric acid followed by 10-15 min incubation on 
ice,  and  centrifuged  to  sediment  the  proteins.  The  formation  of  1-NG  was  
determined from the supernatant aliquots by HPLC with fluorescence detector.  
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4.4.3 Glucuronidation assays (III) 
 
The reaction mixture, total volume of 100 µl, contained 50 mM phosphate buffer 
(pH 5.5 - 8.0), 10 mM MgCl2, 2-5 mM UDPGA, UGT-enriched insect membrane, 
HIM  or  HLM,  and  DMSO  for  the  glucuronidation  assay.  In  the  case  of  HIM  and  
HLM, the reaction mixtures also included 10 µg/ml of alamethicin. More detailed 
information on the assay conditions are presented in the original publication III. 
The enzyme source, substrates and inhibitors, were pre-incubated at 37°C for 
5 min in the reaction mixture in the absence of UDPGA, followed by reaction 
initiation with the addition of UDPGA. The glucuronidation reactions were carried 
out at 37°C and the incubation times were 30-60 min depending on the substrate. 
The reactions were terminated by adding 10 µl of 4 M perchloric acid followed by 
cooling on ice for 10 min and subsequent centrifugation at 13,000 rpm for 10 min in 
a bench top centrifuge. The supernatants from the latter centrifugations were 
analyzed by either by LC-MS, or by LC with UV or fluorescence detection.  
The glucuronidation rates were corrected (normalized) according to the enzyme 
expression level (with the exception of UGT2B15), using UGT1A10 as a reference. 
The relative expression level determination was based on immunodetection using 
monoclonal antibodies to the 6 His residues (His-tag) in the C-terminal fusion 
peptide (Kurkela et al., 2007). The relative expression levels in the specific batches 
of recombinant UGTs are reported in the original publication III. 
4.4.4 Automated bidirectional Caco-2 transport assay (IV) 
 
Wells A1-A3, B1-B3, C1-C3 and D1-D3 were used for studying drug transport of 
four different drugs (n=3 for each) in the A-B direction, while in the wells A4-A6, 
B4-B6, C4-C6 and D4-D6 the transport was studied in the B-A direction. Two 
permeability protocols were automated: 1) primary first-stage bidirectional Caco-2 
permeability assay for fast permeating compounds and 2) secondary assay for slowly 
permeating compounds (Fig. 7). In the primary assay the incubations were scheduled 
as short as possible within the technical limits of TECAN workstation (sampling at 
5, 10, 15 and 20 min time points). In the secondary assay samples were taken every 
30 minutes until 120 minutes. Samples were analyzed either with HPLC equipped 
with UV and fluorescence detectors (injected directly from the sample plates) or 







Figure 7. Assay protocol for the automated bidirectional Caco-2 transport assay. 
The monolayers grown on test plate were first washed with buffer (step 1). 
During the equilibration (step 2) a new base plate and a sample plate for donor 
samples were pre-filled (steps 3-4). The equilibration buffer was then discarded 
(step 5), the insert part was transferred onto the new base plate (step 6) and the 
experiments were initiated by adding the receiver volumes and drug solutions 
(step 7-8). Immediately thereafter, a start sample was withdrawn (step 9). In the 
primary protocol the test plate was kept on the warmed carrier during the 
incubations and in the secondary protocol the incubation was carried out in the 
TECAN incubator (step 10). In the primary experiments number of sampling time 
points was four and in the secondary experiments it was three (step 11). After the 
withdrawal of the last receiver sample, end samples were withdrawn from the 
donor compartments (step 12). 
4.4.5 Cytotoxicity assays (IV) 
 
Heterogeneous SRB assay, used in studying toxicity and anticancer activity, is a 
protein staining assay detecting the total cellular protein amount (Skehan et al., 
1990). The automated SRB assay followed the protocol by NCI. Except pre-seeding 
of the test plate, the assay was carried out automated using separate processes (Fig. 
8). The volumes are stated per well. 
 
Figure 8. The Caspase-Glo® 3/7 assay was initiated by adding the compounds into 
the test plate (step 1). After exposure (step 2) the reagent was added (step 3) and 




The homogeneous Caspase-Glo® 3/7 assay kit measures the activation of caspase 
enzymes 3 and 7 in cells undergoing apoptotic cell death (O´Brien et al., 2005). The 
assay was performed according to the instructions by Promega. Two simple 
processes were created and the assay was performed in automated mode after 
seeding the cells into the test plate (Fig. 9). The automated assay process was the 





Figure 9. The sulforhodamine B (SRB) assay was initiated by adding drug 
solutions into the test plate (step 1). After the exposure (step 2) the cells were 
fixed with TCA (steps 3-4), and the cell fixate was washed with mQ-water (step 
5). Then, it was stained with SRB (steps 6-7) and the protein unbound dye was 
removed by washing with dilute acetic acid (step 8). Finally, the protein bound 
dye was dissolved into Trizma® base (steps 9-10) and diluted (step 11) prior to 
the absorbance measurements. 
4.5 Analytical methods 
The multiple glucuronidation products were analyzed by UPLC-MS at Novamass 
Ltd. (Oulu, Finland). Agilent 1100 series HPLC, Shimadzu HPLC or Water Acquity 
UPLC with UV or fluorescence detection were used in house to detect samples from 
the Caco-2 permeability (IV) and glucuronidation experiments (III).  
1-naphthylglucuronide (I, II), sulforhodamine B (IV),  and  erythrosine  (I, IV) 
were detected with Varioskan plate reader, fluorescein (IV) and rhodamine (IV) with 
Wallac Victor® 1420 multilabel counter, and 14C-mannitol (IV), 3H-digoxin (IV) and 
Caspase-Glo® 3/7 reagent with Wallac 1450 Mikrobeta/Trilux scintillation counter. 
The analytical methods are described in more detail in the original publications 






4.6 Data analysis 
4.6.1 Kinetic parameters (I, II, III, IV) 
 
Apparent permeability coefficient, Papp (IV) was calculated according to the 





dtdQ      (1) 
where dQ/dt is cumulative transport rate (nmol/min), A the surface area of the insert 
(0.33 cm2), and C0 the initial donor concentration (nmol/ml). 
 
Efflux ratio (IV) was obtained as a ratio of Papp B-A and Papp A-B. 
 
Probe glucuronidation rate (I, II). The fluorescence intensity was measured at least 
at the 0 and 30 min time points. The readings were collected at two excitation 
wavelengths, 295 and 300 nm with fixed emission to 335 nm, and the area under the 
signal (AUS) of the excitation spectra between 295 and 300 nm was calculated. 
Subsequently, the AUS values were plotted against the fluorescence measurement 
time, and a linear regression line was fitted through the points. The slope value 
(AUS/min) was used as an indicator of the reaction rate.  
 
Km,  Ksi (I, III). The  Km values for substrates were estimated by fitting the 
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where v is the initial velocity of the reaction, S the substrate concentration and Vmax 
the maximum velocity, Km the  substrate  concentration  at  0.5Vmax and Ki the 
dissociation constant for the substrate inhibition interaction. 
 
IC50 (I, III) values for 4-hydroxyindole (I), scopoletin (I), indomethacin (III) and 
diclofenac (III) were estimated by fitting the experimental data to the following 
equation with GraphPad Prism version 4.03 for Windows;  
% inhibition = h
I
IC501
100   ,    (4) 




Growth inhibition % (GI%) (I) was calculated from the measured absorbance values 
according to the following equation (Vichai and Kirtikara, 2006) 





        (5)               
where Ti is the absorbance after drug treatment (t = 48 h), Tz the absorbance 
indicating the protein amount before drug addition (t = 0 h), and C the absorbance of 
the control well indicating free cell proliferation without drug treatment (t = 48 h). 
4.6.2 Correction for compound interference (I, II) 
 
The assay signal in the UGT1A6 screen was corrected in the cases when interference 
was observed by the test compound with the fluorescent signal of the 1-NG. 
Procedure was modified from Shapiro et al 2009, and in case of decrease in signal, 
calculated as follows: 




AATA    ,   (6) 
where, A0 is the AUS of the reaction mixture, A1 is the AUS of the reference artifact 
sample (2.5 µM of 1-NG in reaction mixture), A2 is the AUS of the artifact sample 
(2.5 µM of 1-NG in reaction mixture with test compound), T1 is the AUS of test 
sample without probe (test compound in reaction mixture), and T2 is the AUS of the 
test sample (probe and investigational compound in reaction mixture). 
If  the  reading  of  the  artifact  sample  was  higher  or  similar  compared  to  the  
reference artifact sample reading, the reading of test sample without probe was 
subtracted from the reading of the test sample (T2 – T1). 
4.6.3 Assay quality (I, II, IV) 
 
Signal to base ratio (S/B) (I, IV) was calculated as the ratio of the signals from the 
means of maximum and minimum signals (n=3) (Zhang et al., 1999a). 
 
 Z´ factor (I, I) was calculated according to the equation (7) (Zhang et al., 1999a). 
The values of 0.5 – 1 (or 0.4 – 1 for cell based assays) indicate excellent assay.  
Z´ = 
minmax
minmax )33(1                (7) 
signal to noise ratio (S/N) (II) according to the formula (8) (Zhang et al., 1999a),  
S/N = 
min
minmax  ,      (8) 
 






max   ,      (9) 
where  in  all  max and  min are the standard deviations of maximum and minimum 
signals  and  max  and  min the means of maximum and minimum signals, 
respectively.  
4.6.4 QSAR analysis (II)  
 
The conformations for each of the 46 compounds were defined with Sybyl-X 
software (Tribos, USA). A single conformation for compounds having rotable bonds 
was randomly picked, and all the structures with assigned Gasteiger-Huckel charges 
were first energy minimized using the standard Tripos force field (Powell method 
and 0.05 kcal/(mol.Å) energy gradient convergence criteria). 
 
Support vector machine (SVM) models 
The 46 compounds were classified as strongly interacting (0-40% of the probe 
glucuronidation rate in the presence of the compounds compared to that in the 
absence of compounds), moderately interacting (40-70%), and non-interacting 
molecules (70-100%). For each of the compounds, 856 molecular descriptors were 
calculated, of which 712 were further used in the model development.  
The SVM model was developed with a training set of 31 compounds using 
LIBSVM software (Chang and Lin, 2011). The rest 15 compounds were used as an 
external test set. Relative importance of each of the descriptors in classification was 
evaluated by F-score. In practise, the model was developed by adding features of the 
highest F-scores one after another until the validation accuracy decreased. The 
model giving the best accuracy (Eq. 10), sensitivity (Eq. 11), specificity (Eq. 12) and 
Matthews  correlation  coefficient  (MCC)  (Eq.  13)  was  chosen  after  10-fold  cross-
validation.  
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in which, TP is the number of true positives, TN is the number of true negatives, 
FP is the number of false positives and FN is the number of false negatives. 
 
3D-QSAR (CoMFA/CoMSIA) models  
Compounds were first clustered based on their chemical structures with a hierarchial 
clustering program in Sybyl-X software. The largest of the three clusters, which 
contained in total 35 compounds and covered the whole data range, was chosen for 
3D-QSAR modelling. Compounds were further divided into a training set (26 
compounds) and a test set (9 compounds).  
First, alignment of the training compounds were tried with several ligand-based 
approaches. CoMFA and COMSIA molecular fields were then calculated for the 
aligned compound set using the QSAR module of Sybyl-X software.  
CoMFA and CoMSIA models were developed using a conventional stepwise 
procedure. The leave-one-out cross validation (LOOCV) was performed to 
determine optimum number of components leading to the highest cross-validation 
coefficient q2 (Eq. 14) and the lowest standard error of prediction (SEP). 
 
q2 = 1 –  ,                                             (14) 
 
where, Ypredict is  a  predicted  pGlu,  Yexperimental is  an  experimental  pGlu,  Ymean is 
the best estimate of the mean of all values that can be predicted.  
After  that,  non-cross-validation  analysis  was  performed to  derive  the  final  PLS 
regression models with the explained variance r2, standard error of estimate (SEE) 
and F-ratio. The CoMFA and CoMSIA fields were graphically represented in 
contour maps, where the coefficients were generated using the field type 
‘‘Stdev*Coeff’’. Locations of favored and disfavored fields were presented at 80% 
and 20% levels, respectively.  
In order to test the real predictive ability of the trained CoMFA and CoMSIA 
models, the pGlu values of the external validation set (9 compounds) were predicted 
using the same CoMFA and CoMSIA calculation parameters as those used to 
generate the models. The non-cross validated analyses were used to make 
predictions of the probe glucuronidation rate (pGlu) of compounds from the test set 
and to display the coefficient contour maps. The actual versus predicted probe 
glucuronidation rate (pGlu) of the test compounds were fitted by linear regression, 
and the r2pred (Eq. 15), SEE, and F ratio were determined. 
 
r2pred = 1 – ) )
)
                       (15)
  
In Equation (15), Ypredict(test) and Y(test) indicate predicted and experimental probe 
glucuronidation rates (pGlu) of the test set compounds, respectively, and Ymean 
indicates the mean probe glucuronidation rate (pGlu) of the training set. 
. 
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5 Results and discussion 
5.1 HTS assay for UGT1A6 (I, II) 
5.1.1 Detection of probe reaction (I) 
 
The core of the assay is a probe reaction, in which 1-naphthol is glucuronidated by 
recombinant UGT1A6 into a highly fluorescent metabolite, 1-NG (Fig. 10). The 
formation of 1-NG is followed with a plate reader by detecting the excitation spectra 
(295-300 nm) at fixed emission wavelength (335 nm). This analytical approach 
allowed  the  separation  of  the  1-NG  signal  from  the  signal  produced  by  the  
components of the reaction mixture. In the assay system, reaction mixture contained 
insoluble material, such as biological membranes and traces of other cell 
components,  which are prone to interfere with the signal detection. The stability of 
the detected signal was further increased by using of the area under the excitation 
signal (AUS), instead of a single wavelength measurement. 
This probe-based assay is the first of a kind for detecting compound interactions 
with  any  of  the  UGT  isoforms.  The  possibility  to  follow  the  probe  reaction  at  the  
product site, intead of detecting only the disappearance of the probe substrate 
(Collier et al., 2000; Broudy et al., 2001; Trubetskoy et al., 2007), helps to avoid 
several possible artefacts. In addition, the possibility to detect the 1-NG formation 
without secondary reactions or purification steps, unlikely in few of the previously 
reported assays (Trubetskoy and Shaw, 1999; Di Marco et al., 2005; Kleman-Leyer 
et al., 2009; Larson et al., 2010), reflects also to the costs of the assay. 
 
 
Figure 10. Basic principle of the UGT1A6 screening assay. The assay is based on 
detecting the increase in fluorescence when the probe 1-napthol is 
glucuronidated into highly more fluorescent 1-naphthylglucuronide (1-NG). The 
interaction of the test compound with the enzyme is detected as decreased rate of 






5.1.2 Optimal conditions for the probe reaction (I) 
 
The reaction conditions for the conversion of 1-naphthol into 1-NG, were optimized 
to yield high enough signal separation. A probe concentration of 5µM (Km 7.7 ± 
0.7 µM for 1-naphthol) and reaction time of 30 min with 2.5 µg of total protein per 
well, without stirring, gave the best linearity and signal separation with r2 of 0.998 
and S/B of 3.9, respectively. The  optimal  pH  for  the  conversion  was  found  to  be  
around pH 7.5 (Fig. 11a) and, the highest glucuronidation rate was reached in 
phosphate buffer (Fig. 11b). As expected, increase in the DMSO concentration from 
1% to 10% decreased the probe glucuronidation rate (Fig. 11c). Nevertheless, the 
signal separation was still acceptable with S/B 3.0 at 5% DMSO. 
 
Figure 11. Effects of a) pH, b) buffer, and c) DMSO concentration on the probe 
reaction rate (n=2, CV%  5). The buffers tested were C; citrate (pH 6.0), A; 
acetate (pH 6.0), T; Tricine (pH 7.5), M; MOPS (pH 7.5), M-T; MOPS-Tricine 
(pH 7.0) and P; phosphate (pH 7.4). The phosphate buffer at pH 7.4 with 5% of 
DMSO was selected for the screen. Copyright © (2011) Mary Ann Liebert, Inc. 
Reprinted with the permission. 
5.1.3 Inhibition assay (I) 
 
The HTS assay is based on the assumption that the interaction of the test compound 
with the recombinant human UGT1A6 affects the rate at which the fluorescent 1-NG 
is formed. In the case of inhibitors, that is detected as a lower rate of fluorescence 
increase in comparison to the reaction with only the enzyme and the probe.  
First, the effect of scopoletin and 4-hydroxyindole, two good substrates of 
UGT1A6 (Luukkanen et al., 2005; Manevski et al., 2010), on the fluorescent signal 
were determined to obtain preliminary information on the signal range of the assay at 
different compound concentrations. The inhibition patterns obtained with the HTS 
assay and a reference HPLC method with fluorescence detector were similar 
showing IC50 values of 108±7 and 148±6 µM for 4-hydroxyindole, and 969±58 and 
869±63 µM for scopoletin, respectively. The good correlation of the results obtained 
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with both the methods also in detecting interactions with sets of NSAIDs and 
salicylic acid derivatives further convinced the functionality of the assay (Fig. 12).  
 
Figure 12. Results obtained with the HTS assay and the reference HPLC method for 
the non-steroidal anti-inflammatory drugs and salicylate derivatives (SS, sodium 
salicylate; 5-BSA, 5-bromosalicylic acid; 5-CSA, 5-chlorosalicylic acid; 5-FSA, 
5-fluorosalicylic acid) at 500 µM. Copyright © (2011) Mary Ann Liebert, Inc. 
Reprinted with the permission. 
The plate uniformity and signal variation tests with 4-hydroxyindole 
demonstrated robust probe glucuronidation behaviour throughout the plate and 
acceptable separation of the minimum and maximum signals. For all the three plates 
also the quality parameters, including Z´ factor values of 0.5 or higher, indicated an 
excellent HTS assay (Table 6).  
Table 6. Assay quality parameters for the UGT1A6 assay. The parameters were 
calculated from the raw data AUS values after 30 min incubation and the 
obtained slope values (AUS/min). Copyright © (2011) Mary Ann Liebert, 
Inc. Reprinted with the permission. 
 Plate 1 
Raw data          Slope 
Plate 2 
Raw data          Slope 
Plate 3 
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Based  on  the  data  and  earlier  findings  on  generally  low  affinities  of  substrates  
and inhibitors towards the UGTs (reviewed in Kiang et al., 2005), it was obvious that 
fairly high compound concentrations, in the range of 100-500 µM, would be needed 
to be used in the screening. Adding to this, also the fact that the excitation 
wavelengths of 1-NG are low (295-300 nm), interference with a large portion of the 
test  compounds  was  inevitable.  However,  this  drawback  of  the  assay  was  
successfully overcome by applying an arithmetic correction procedure (Shapiro et 
al., 2009). 
5.1.4 Screening a set of compounds (I, II) 
 
The  developed  HTS  assay  was  succesfully  used  for  the  screening  of  46  
compounds, including  14 benzoic acid, 4 naphthalene, 11 phenol, 5 carboxylic acid, 
3 indole, 2 flavonoid and 6 coumarin derivatives and coffein, towards the 1-naphthol 
glucuronidation at the compound concentration of 500 µM. The observed 
interactions with the probe glucuronidation covered the full range of the assay signal, 
from almost fully inhibited reaction to no interaction (Fig. 13). As the assay detects 
only the effect of a compound on probe glucuronidation, compounds decreasing the 
glucuronidation rate may be substrates for the UGT1A6, and thus, compete with the 
probe glucuronidation. Alternatively, they may only interfere with the enzyme 
catalysis of the probe substrate, without being glucuronidated by the UGT1A6.  
 
Figure 13. Range of the data obtained in screening 46 compounds. The compound 
names related to the ID numbers can be found from the original manuscript (II). 
The newly developed and optimized UGT screening assay was demonstrated to 
be effective in finding potential inhibitors and/or substrates of the UGT1A6. 
Although the current assay was developed and optimized using only UGT1A6 as the 
enzyme, this assay could probably be adapted to several other UGTs, since many of 
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5.2 Classification and 3D-QSAR models for UGT1A6 (II) 
5.2.1 SVM model 
 
SVM model for the classification of compounds into three classes based on their 
effect on 1-naphthol glucuronidation by human UGT1A6 was developed. The 
derived model was based on ten molecular descriptors characterizing atomic mass, 
nature of carbon in the molecules, molecular distance edge, hybridization state, 
polarization, polarizability, electrotopologigal state, size, logP, electronegativity and 
dipole  moment.  The  prediction  performance  of  the  model  is  presented  in  Table  7.  
The specificities higher than sensitivities for both the training and test set 
compounds indicated that the model is able to find more reliably the compounds that 
do not belong to a certain class than the compounds that would belong to a certain 
class. These are in line with the earlier findings, both in terms of prediction 
performance and important descriptors for the molecular recognition and catalysis by 
the UGT enzymes (Ethell et al., 2002; Smith et al., 2003; Dong and Wu, 2012).    
Table 7. Prediction performance of the SVM model. 
 Accuracy (%) Specificity (%) Sensitivity (%) MCC 
Training set 77 91 83 0.75 
External test set 67 83 66 0.55 
5.2.2 3D-QSAR models 
 
Of the several methods tested for aligning the training dataset, the preliminary 
CoMFA model developed, based on Surflex-Sim Flexible alignment (Fig. 14), gave 
the best predictive performance (r2cv 0.62 and r2ncv 0.95). It was, therefore, chosen as 
the basis for further CoMFA and CoMSIA model development.  
 
 
Figure 14. Surflex-Sim Flexible alignment of the training set in the grid box (2Å). 
 
41 
The CoMSIA analysis capable of taking into account steric, electric, hydrophobic 
and hydrogen bonding donor and acceptor fields provided more statictically reliable 
model than the CoMFA (Table 8). For this data set (compounds detailed in the 
manuscript II), the contributions of hydrogen bond donor fields were the most 
important (0.36), but also electric, hydrophobic and hydrogen bond acceptor fields 
had significant contributions.  
Table 8. Prediction performance parameters of CoMFA and CoMSIA models 
based on Surflex-Sim Flexible alignment.  
 Parameter 
    q2          r2        NC        SEP     F-value    r2pred 
Contributors 
      S            E           H          D           A 
CoMFA 0.62 0.94 5 7.5 84 0.68 0.39 0.61 - - - 
CoMSIA 0.76 0.89 4 0.11 107 0.74 0.03 0.20 0.22 0.36 0.17 
r2 is the q2 without the leave-one-out cross-validation; NC, number of components from PLS 
analysis; S, contribution of steric fields; E, contribution of electric fields, H, contribution of 
hydrophobic fields; D, contribution of hydrogen bond donor fields; and A, contribution of 
hydrogen bond acceptor fields 
 
Also the scatter plots presenting the correlation of predicted and experimental 
probe glucuronidation rates revealed the better performance of the CoMSIA model 
(Fig. 15). The CoMSIA model was able to predict the external test of 9 compounds 
with the r2pred of 0.74 and CoMFA with the r2pred of 0.68.  
 
 
Figure 15. Scatter plots of the experimental probe glucuronidation rate values 
(pGluexp) versus predicted probe glucuronidation rate values (pGlupred) for the 
CoMFA (A) and CoMSIA (B) models. Open circles ( ) represent the predictions 
of training set compounds after leave-one-out crossvalidation, crosses (x) 
represent the predictions of training set compounds without crossvalidation, and 
filled triangels ( ) represent the predictions of test set compounds. 
 
 
Results and discussion 
42 
The CoMFA contour plots are able to define the regions where bulky or charged 
functional groups would either be favourable or unfavourable for the interaction with 
the UGT1A6 (Fig. 16a). In addition to CoMFA fields, hydrophobic, hydrogen bond 
donor and acceptor fieds are presented as contour plots (Fig. 16b-d). The steric and 
electrostatic fieds obtained with CoMSIA analysis were similar to those obtained in 
CoMFA analysis. The CoMSIA fields further highlight the importance of 
hydrophobic and hydrogen bonding groups for compound interactions with 
UGT1A6.    
 
Figure 16. Contour maps of CoMFA and CoMSIA fields using the compound 16, 
naphthalene-1,2-diol, as a representative structure. a) In CoMFA, green contour 
indicates regions where bulky groups, blue contours indicate the regions where 
an increase in positive charge, and red contours indicate regions where increase 
in negative charge are favourable for the compound interaction with the 
UGT1A6. Whereas, yellow contours indicates the area where large substituents 
are unfavorable for the interaction. In CoMSIA, b) orange contours indicate 
regions where hydrophobic groups are favorable for the interaction, c) magenta 
represents areas where HB acceptors are favorable and red areas where they 
are unfavourable for the interaction, and d) cyan represents areas where HB 




5.3 Effect of pH on compound interactions with human 
UGTs (III) 
5.3.1 Indomethacin and diclofenac glucuronidation in HLM and HIM 
 
More than one glucuronide products for diclofenac and indomethacin, NSAIDs 
bearing a carboxylic acid group in their structure, were found in LC-MS 
chromatograms after incubations in HLM at pH 7.4. In the case of indomethacin, the 
glucuronide peaks were two, whereas in case of diclofenac two main glucuronides, 
and traces of a third one, were detected. The decrease in pH from 7.4 to 6.0 resulted 
in a decrease in the relative sizes or disappearance of the minor peaks. These 
findings suggested that the main peaks represented the respective acyl-glucuronides, 
metabolites resulting from the conjugation of the carboxylic acid with glucuronide 
acid. The acyl-glucuronides of both drugs are known to be unstable at physiological 
conditions and undergo acyl-glucuronidation (Spahn-Langguth and Benet, 1992).  
In the further experiments with human microsomes, the results analyzed in UPLC 
with  UV detection  revealed  that  lowering  the  reaction  pH from 7.4  to  6.0  led  to  a  
2-fold increase in the rate of indomethacin glucuronidation by both the HIM and 
HLM (Table 9). In the case of diclofenac glucuronidation, on the other hand, the 
results  with  HLM  were  similar  at  both  pH  values,  while  the  rate  of  the  HIM-
catalyzed reaction was clearly higher at pH 6.0 than at pH 7.4. 
Table 9. Glucuronidation rates (pmol/min/mg) of diclofenac and indomethacin by 
HIM and HLM. Copyright © (2012) Elsevier. Reprinted with the 
permission. 
 Diclofenac   
  pH 6.0                       pH 7.4 
Indomethacin 
  pH 6.0                       pH 7.4 
HIM 
HLM 
  196 ± 2 
1041 ± 6 
   168 ± 3 
 1051 ± 2 
65.5 ± 1.6 
  220 ± 9 
  32.9 ± 1.8 
   116 ± 6 
5.3.2 Effect of pH on glucuronidation of model compounds 
 
Glucuronidation of indomethacin and diclofenac by 19 human UGTs were screened 
at substrate concentration of 100 µM at pH 6.0 and 7.4. The results, corrected for the 
relative expression level of each UGT (except for UGT2B15), are presented in 
Figure 17. Diclofenac was mainly glucuronidated by UGT isoforms 1A10, 2B7 and 
2B17. pH affected most the glucuronidation of diclofenac by UGT1A10 and 
UGT2B17. Whereas, the main isoenzymes catalyzing indomethacin glucuronidation 
were 1A10, 2B7 and 2A1, which were all affected by the pH change. Overall, the 
results revealed that the effect of reaction pH on the rate of indomethacin and/or 
diclofenac glucuronidation varied among the individual UGTs. For example, the 
glucuronidation of both indomethacin and diclofenac by UGT1A10 was highly 
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stimulated by lowering the reaction pH from 7.4 to 6.0, whereas in the case of 
UGT2A1, only the indomethacin glucuronidation rate was strongly stimulated by 
lowering the reaction pH from 7.4 to 6.0. 
 







































Figure 17. Diclofenac and indomethacin glucuronidation rates (normalized) of 
individual human UGTs at pH 7.4 (white) and 6.0 (gray). The significance of the 
change between the two pH values for each of the UGT is marked as: *p=0.05, 
**p=0.005, ***p=0.001. Copyright © (2012) Elsevier. Reprinted with the 
permission. 
The effect of pH on the glucuronidation rates of diclofenac and 4-MU by 
UGT1A10 and UGT2B15, and that of indomethacin by UGT1A10 only, were further 
examined in the pH range of 5.5-8.0 (Fig. 18). Neither enzyme exhibited detectable 
diclofenac glucuronidation at pH 5.5, but the differences between the two enzymes 
at pH 6.0 were large. The optimal pH value for UGT1A10 in both diclofenac and 
indomethacin glucuronidation is 6.0, while UGT2B15 is practically inactive at this 
pH value. The lowest pH at which the UGT2B15 catalyzed diclofenac 
glucuronidation was 6.5, and the optimal reaction pH for this enzyme was 7.0. In 
addition, the effect of pH on the glucuronidation of 4-MU, a non-ionized compound, 
by the UGT1A10 and UGT2B15 was examined. The results indicated that while the 
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pH “profile” of UGT2B15 in diclofenac and 4-MU glucuronidation reactions were 
very similar, UGT1A10 glucuronidates 4-MU more efficiently at higher pH values 
contrary to the highest glucuronidation rates of diclofenac and indomethacin at pH 
6.0.  
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Figure 18. Effect of pH on UGT1A10-mediated glucuronidation of diclofenac, 
indomethacin and 4-methylumbelliferone (4-MU), and on UGT2B15-mediated 
glucuronidation of diclofenac and 4-MU. Copyright © (2012) Elsevier. 
Reprinted with the permission. 
Kinetic analyses of the diclofenac glucuronidation by the UGT1A10 and 
UGT2B7 were undertaken in order to get more detailed information on how the 
lower reaction pH stimulated the glucuronidation activity. It was found out that 
lowering the reaction pH resulted in a lower Km value for the substrate, and a higher 
Vmax value with both the isoforms (Table 10). However, the difference in Vmax values 
was much more pronounced in UGT1A10. Also the increased affinity of diclofenac 
towards the UGT1A10 led to an observed substrate inhibition. The large differences 
between the pH effects on the UGT1A10 and UGT2B7 strongly suggest that changes 
in the enzyme, probably protonation of a yet-unidentified amino acid side chains, 
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Table 10. Kinetic constants for diclofenac glucuronidation by UGT1A10 and 
UGT2B7, as well as for 1-naphthol glucuronidation by UGT1A6 at pH 
6.0 and 7.4. Ksi is the substrate inhibition constant. Copyright © (2012) 








     Km (µM) 
     Ksi (µM) 
     Vmax (pmol/min/mg) 
 
    94 ± 9          
  672 ± 96 
  458 ± 25      
 
  25 ± 1 
 






    6.8 ± 1 
 
3318 ± 101 
pH 7.4 
     Km (µM) 
     Ksi (µM) 
     Vmax (pmol/min/mg) 
 
  153 ± 15 
   
  196 ± 8 
 
  55 ± 3 
 






     5.1 ± 0.3 
  1639 ± 215 
  5860 ± 102 
5.3.3 Effect of pH on inhibition potential 
 
Effect of pH on the inhibition potential of diclofenac and indomethacin towards 
1-naphthol glucuronidation by UGT1A6 was studied to find out if the reaction pH 
affects the binding of the compounds to UGT1A6, an isoform that does not 
glucuronidate neither of the compounds (Fig. 17). UGT1A6 was previously reported 
to be sensitive to inhibition by diclofenac when the assay was carried out at pH 7.4 
(Uchaipichat et al., 2004; original publication I).  
First, the effect of pH was assayed on the 1-naphthol glucuronidation activity of 
UGT1A6 at pH 6.0 and 7.4. The results showed that lowering the reaction pH from 
7.4 to 6.0 strongly reduced the Vmax of UGT1A6 in 1-naphthol glucuronidation, and 
practically eliminated the substrate inhibition that was clear at pH 7.4 (Table 10). 
The pH effect on the Km value of UGT1A6 for 1-naphthol was mild, however. Due 
to this, the subsequent inhibition analyses were carried out in the presence of the 
same substrate concentration, 5 µM. The inhibition profiles showed that both the 
drugs inhibited the 1-naphthol glucuronidation activity of UGT1A6 more effectively 
at pH 6.0 (Fig. 19). This is in line with the higher affinity of UGT1A10 for 
diclofenac at pH 6.0 than at pH 7.4 (Table 10). In addition, diclofenac was 
significantly more effective as a UGT1A6 inhibitor than indomethacin at the two pH 
values. The derived IC50 values for diclofenac were 37 and 85 µM at pH 6.0 and 7.4, 
whereas they were 290 and 440 µM for indomethacin, respectively.  
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Figure 19. Effect of pH on the inhibition of 1-naphthol by diclofenac (A) and 
indomethacin (B). The 1-naphthol concentration was 5 µM. Copyright © (2012) 
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5.4 Automation feasibility (IV) 
5.4.1 Implementation of assays on a robotic workstation 
 
Quality of the liquid handling highly affects the quality of the results. In the three 
cellular assays, Caspase-Glo 3/7, sulforhodamine B and bidirectional Caco-2 
transport assay, the liquid handling parameters were adjusted to acquire acceptable 
precision without interfering with the assay system. The critical steps and optimized 
parameters are listed in Table 11. In the assays studied, tolerance to the mechanical 
stress caused by the pipetting varied. The adherent Caco-2 and DU-145 cells and the 
differentiated Caco-2 monolayers required lowered dispensing speeds. In the SRB 
assay,  the  addition  step  of  TCA  had  to  be  done  extremely  slowly.  Too  high  a  
dispense speed could have caused the fluid shearing forces to interfere with the 
fixation of cell  proteins (Skehan et  al.,  1990).  Removal of the supernatant after the 
fixation was also critical. Differentiated Caco-2 monolayers endure normal 
aspiration speeds as long as the tips do not touch the cell monolayer. Thus, the tips 
were configured to move as close to the cell monolayer as possible to minimize dead 
volume in the apical chamber. Even in the optimized protocol a dilution of 
16.2 ± 1.7% was observed in drug solutions added into the apical chamber.  
Table 11. Liquid handling parameters and settings for the automated assays. 
Copyright © (2010) SAGE Publications. Reprinted with the permission. 
 Step Problem Critical 
parameter 
Solution 
Caspase Glo® 3/7 
     Process 1 
 
     Process 2 
 
1. Drug addition 
 










DS 200 µl/s 
decontamination step 
DS 200 µl/s 
SRB 
     Process 1 
      




     Process 3 
 
1. Drug addition 
 









precipitation in tubing 
protein detachment, 
background signal  












DS 200 µl/s 
cleaning step 










5. Buffer removal 
 
7. Buffer addition 
8. Drug addition 
9./12. Donor samples 
11. Receiver samples 
 
monolayer integrity , 
 
monolayer integrity , 
dead volume 
monolayer integrity  
monolayer integrity  
monolayer integrity  











DS 200 µl/s 
TH z-max-0.5xmm* 
DS 200 µl/s 
TH z-max-0.5xmm* 
DS 200 µl/s 
DS 200 µl/s 
TH z-max-0.5xmm  
TH z-max-0.5xmm 
DS, dispense speed; TC, tip/tubing cleaning; AS, aspiration speed; TH, tip height 
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Since only fixed tips were used in the Caspase-Glo® 3/7  and  SRB  assays,  a  
decontamination step, wash of tips with DMSO, was needed to prevent carry-over. 
In addition, a cleaning step with pure DMEM or RPMI 1640 medium was needed to 
remove the serum remnants from the pipette tubing, and to avoid foggy-like 
precipitation to appear randomly in the wells. 
5.4.2 Optimization of assays 
Caspase-Glo® 3/7 assay 
Optimization and standardization of the automated apoptosis assay were performed 
on Caco-2 and DU-145 cells. With Caco-2 cells 25 000 cells per well (Fig. 20a), 
exposure time of 12 hours (Fig. 20b) and reagent incubation time of 30 minutes (Fig. 
20c) gave the optimimal apoptosis signal. With vinblastine a Z´ factor of 0.7 with an 
S/B value of 1.7 indicated succesfull assay. Based on the dose-responce curves, 
concentrations 0.1 (min) and 50 µM (max) were suggested to be used in screening. 
With DU-145 cells a single exposure time could not be chosen, since the activity of 
vinblastine was the highest after 8 and 12 hours of exposure, and decreased 
markedly during prolonged incubation, while the activity of doxorubicin was only 
detectable after 24 hours of exposure (Fig. 20e). Therefore, a robust screen could not 
be set up with DU-145 cells. 
 
Figure 20. Optimization of cell number (a,d), exposure time (b,e) and reagent 
incubation time of the automated Caspase-Glo® 3/7 assay on Caco-2 (a-c) and 
DU-145 (d-f) cell lines. For the standardization, dose-response curves were 
determined on both vinblastine (VBL) and doxorubicin (DOX) (c, f). Copyright © 
(2010) SAGE Publications. Reprinted with the permission. 
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Sulforhodamine B assay 
Optimization and standardization of the SRB assay was performed with both the cell 
lines. With the DU-145 cells, the linear increase in total protein up to 72 hours 
(Fig. 21a) and the sigmoidal dose-response profile with an S/B of 2.2 for vinblastine 
confirmed the choice of 10 000 cells per well as the appropriate cell number 
(Fig. 21b). Sigmoidal dose-response profiles were obtained for vinblastine, 
doxorubicin and 5-fluorouracil with GI50 values of 0.8 nM, 81 nM and 4.8 µM, 
respectively (Fig. 21c). Z´ factors for all the compounds were 0.4 or higher 
indicating successful cell-based assay (Falconer et al., 2002). Based on these data, 
the cell number of 10 000 cells per well and concentrations 1 nM (min) and 10 µM 
(max) were chosen for the screening with the DU-145 cells. 
With Caco-2 cells, the optimization of SRB screen was not successful. 
Proliferation  of  the  cells  was  not  linear  at  the  lowest  cell  numbers  of  5  000  and  
10 000, and no reliable dose-response correlations could be defined. 
 
Figure 21. Optimization and standardization of automated SRB assay on DU-145 
cell line. a) Growth curves for the DU-145 cells and b) the sigmoidally fitted 
dose-response profiles for vinblastine on three different cell numbers. c) Dose-
response profiles for vinblastine (VBL) (solid), doxorubicin (DOX) (dashed) and 
5-fluorouracil (5-FU) (dotted) on the DU-145 cells. Copyright © (2010) SAGE 
Publications. Reprinted with the permission. 
Bidirectional Caco-2 permeability assay 
Two automated protocols were set up for the bidirectional Caco-2 permeability 
experiments: the primary and secondary protocols with sampling intervals of 5 and 
30 minutes without and with stirring, respectively. To reveal the significance of 
lacking stirring in the primary protocol, the high permeability compounds were 
evaluated using both protocols: the Papp values did not differ markedly between these 
two protocols (Fig. 22a).  
The Caco-2 permeability experiments were standardized using both high and low 
permeability compounds and MDR1 efflux substrates. The high permeability 
compounds (metoprolol, propranolol, antipyrine, ketoprofen, carbamazepin) had Papp 
(A-B) values >20x10-6 cm/s (Fig. 22b), while the low permeability compounds 
(mannitol, atenolol, nadolol, hydrochlorthiazide, ranitidine) had Papp (A-B) values 
<1x10-6 cm/s. Hence, the difference was at least 20 fold resulting in a Z´ factor of 0.8 
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(nadolol vs. metoprolol). The efflux ratios for passively permeating compounds and 
MDR1 substrates (rhodamine 123, vinblastine and digoxin) were <3.5 and >7, 
respectively, which yields a Z´ factor of 0.5 (digoxin vs. nadolol). 
 
Figure 22. Optimization and standardization of automated Caco-2 permeability 
experiments. a)  Papp (A-B) values for the high permeability compounds were 
defined on both the automated primary and secondary permeability protocol to 
reveal the effect of lacking the stirring. b) The standardization of the automated 
bidirectional Caco-2 permeability experiments was done using the FDA 
recommended high and low permeability model compounds and the substrates of 
MDR1 efflux protein. Copyright © (2010) SAGE Publications. Reprinted with 
the permission. 
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5.5 General discussion 
During this thesis work, three automatable in vitro transport and metabolism assays 
were developed and/or utilized: a UGT1A6 screen (I, II), glucuronidation assays 
(III), and bidirectional Caco-2 permeability assay (IV). In addition, cytotoxicity 
assays  sulforhodamine  B  (SRB)  (IV) and Caspase-Glo® 3/7  (IV)  were  part  of  the  
studies. All the assays were transferred on a robotic workstation and run automated 
in the course of the studies, with the the exception of the glucuronidation assays 
(III).  
The ease of implementing the assays on the robotic workstation was highly 
dependent on the amount of the liquid handling steps, properties of the liquids and 
sensitivity of the biological model system for mechanical stress. The developed 
UGT1A6  screen  (I, II)  and  the  commercial  assay  kit  Caspase-Glo® 3/7  (IV) were 
easy to automate, whereas the SRB assay (IV) and the bidirectional Caco-2 transport 
assay (IV) were more challenging. Although the glucurodation assays were not 
automated in this study, they would be fairly easy to set up on a robotic workstation 
by slightly modifying the protocol used in the UGT1A6 screen. 
The assays were automated on a Tecan Genesis RSP 150/8 workstation. This 
particular workstation was in the first place designed for the bidirectional transport 
assays in 24-well format, and was not optimal for the 96-well assays. In principle, 
the add-mix-measure type of assay does not require such a versatile robotic system, 
but  the  benefits  of  automation  would  be  achieved  already  with  a  simple  liquid  
dispenser, preferably equipped with a 96-tip head and connected to a plate storage 
system. 
The overall throughput of an assay is not affected only by the time of the assay 
execution, but also by the time used in preparations before and after the actual assay, 
and in the analysis of the samples. It is always beneficial, if the biological model 
system can be prepared in advance at bigger batches, aliquoted, stored frozen and 
thawn on the assay day, as it was done with the recombinant enzyme preparations (I, 
II, III) and microsomes (I, II). In the cellular assays that is usually not possible, but 
the cell maintenance and culturing of the cells have to be coordinated to provide the 
cellular models at a defined timepoint. Depending on the desired properties of the 
cellular system, it may take from days to weeks to prepare the cells for the assays 
(IV). Obviously, also the fast plate reader-based analytical methods, which detect 
either the compound fluorescence (I, II), luminescence (IV) or absorbance (IV), are 
often preferred over the more time-consuming LC or LC-MS analysis (III, IV).  
The throughput of an assay is an important determinant of its utilization potential 
for screening high number of compounds. The more complex, and thus the more 
laborious, assays often provide more in vivo relevant results. The results obtained in 
assays performed with model systems highly mimicking the in vivo intestinal wall, 
such as the bidirectional Caco-2 transport assays, are a sum of multiple processes, 
such as passive membrane permeability, passage via active uptake, and the impact of 
efflux transporters and intracellular metabolism. Although single transporters or 
enzymes separated from their natural cellular environment are useful in detailed 








1. A new fluorescent HTS assay was developed based on 1-naphthol 
glucuronidation by UGT1A6 for the detecting of drug interactions 
with the human recombinant UGT1A6 (I).  
 
2. The developed HTS assay for the UGT1A6 was succesfully used to 
provide a data set on compound interactions with the UGT1A6. The 
data was further used in developing a SVM classification method and 
3-D QSAR models based on COMFA and COMSIA analysis (I, II).   
 
3. The effect of pH on the interactions of diclofenac and indomethacin 
with human UDP-glucuronosyltransferases was found to be highly 
variable and enzyme specific (III). 
 
4. Three different cellular assays were succesfully automated on a 
robotic workstation by optimizing the critical liquid handling 
parameters and experimental set-ups in each assay. The benefits 
gained by automation were dependent on the properties of the assay 
protocols and the instruments. The simplest assay was the most 
suitable for automation, but also the more challenging assays benefit 
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